AU2010321278A1 - Method for production of F-18 labeled glutamic acid derivatives - Google Patents

Method for production of F-18 labeled glutamic acid derivatives Download PDF

Info

Publication number
AU2010321278A1
AU2010321278A1 AU2010321278A AU2010321278A AU2010321278A1 AU 2010321278 A1 AU2010321278 A1 AU 2010321278A1 AU 2010321278 A AU2010321278 A AU 2010321278A AU 2010321278 A AU2010321278 A AU 2010321278A AU 2010321278 A1 AU2010321278 A1 AU 2010321278A1
Authority
AU
Australia
Prior art keywords
formula
branched
tert
compound
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2010321278A
Other versions
AU2010321278B2 (en
Inventor
Mathias Berndt
Thomas Brumby
Matthias Friebe
Keith Graham
Christina Hultsch
Heribert Schmitt-Willich
Franziska Wagner
Hans-Jurgen Wester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Molecular Imaging SA
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AU2010321278A1 publication Critical patent/AU2010321278A1/en
Assigned to PIRAMAL IMAGING SA reassignment PIRAMAL IMAGING SA Request for Assignment Assignors: BAYER PHARMA AKTIENGESELLSCHAFT
Application granted granted Critical
Publication of AU2010321278B2 publication Critical patent/AU2010321278B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)

Abstract

This invention relates to methods, which provide access to F-18 labeled glutamic acid derivatives.

Description

WO 2011/060887 PCT/EP2010/006766 Method for production of F-18 labeled glutamic acid derivatives FIELD OF INVENTION This invention relates to methods, which provide access to F-18 labeled 5 glutamic acid derivatives. BACKGROUND Over the last few years, in vivo scanning using Positron Emission Tomography (PET) has increased. PET is both a medical and research tool. It is used in a io variety of medical applications, including imaging of the brain, tumors, and components of cardiovascular system. Radiotracer consisting of a radionuclide bound to a biologically active compound is used for in vivo imaging of disorders. The radionuclides used in PET scanning are typically isotopes with short half 15 lives such as C-11 (-20 min), N-13 (-10 min), 0-15 (-2 min), Ga-68 (-68 min) or F-18 (-110 min). Due to their short half lives, the radionuclides must be produced in a cyclotron (or generator) which is not too far away in delivery-time from the PET scanner. These radionuclides are incorporated into biologically active compounds or biomolecules that have the function to vehicle the 20 radionuclide into the body through the targeted site e.g. tumor. F-1 8 labeled compounds are gaining importance due to its availability as well as development of methods for labeling biomolecules. It has been shown that some compounds labeled with F-18, produce images of high quality. 25 Additionally, the longer lifetime of F-18 would permit longer imaging times and allows preparation of radiotracer batches for multiple patients and delivery of the tracer to other facilities, making the technique more widely available to clinical investigators. Additionally, it has been observed the development of PET cameras and availability of the instrumentation in many PET centers is 30 increasing. Hence, it is increasingly important to develop new tracers labeled with F-18.
WO 2011/060887 PCT/EP2010/006766 -2 The PET tracers currently used in tumor diagnosis have some undisputed disadvantages: thus, FDG is preferably accumulated in cells having an elevated glucose metabolism; however, under different pathological and physiological conditions, as also in elevated glucose metabolism in the cells and tissues 5 involved, for example infection sites or wound healing (summarized in J. Nucl. Med. Technol. (2005), 33, 145-155). Frequently, it is still difficult to ascertain whether a lesion detected via FDG-PET is really of neoplastic origin or is the result of other physiological or pathological conditions of the tissue. Overall, the diagnosis by FDG-PET in oncology has a sensitivity of 84% and a specificity of io 88% (Gambhir et al., "A tabulated summary of the FDG PET literature", J. Nucl. Med. 2001, 42, 1-93S). The imaging of brain tumors, for example, is very difficult owing to the high accumulation of FDG in healthy brain tissue. In some cases, the F-18 labeled amino acid derivatives currently known are well 15 suited for the detection of tumors in the brain (review): Eur. J. Nucl. Med. Mol. Imaging. 2002 May; 29(5): 681-90); however, in the case of other tumors, they are not able to compete with the imaging properties of the "Goldstandard" FDG. The metabolic accumulation and retention of the current F-18 labeled amino acids in tumor tissue is generally lower than of FDG. 20 Several a-L-amino acids of general formula A have been labeled with fluorine 18 so far. 0 R OH H
NH
2 A Well known are fluorine-18 labeled derivatives, whereas R is bearing an 25 aromatic moiety, e.g.: * FDOPA * 2-fluoro-L-thyrosine " OMFD " Fluoroethyl -L- tyrosine WO 2011/060887 PCT/EP2010/006766 -3 Fluoromethyl -L- tyrosine However, only few examples are described, wherein a F-18 labeled amino acid A is bearing a substituent R without an aromatic moiety: 5 * S-(2-[F-1 8]fluoroethyl)-L-homocysteine / S-(2-[F-1 8]fluoroethyl)-L-methionine (1) (Bourdier et. al, Journal Labeled Compounds and Radiopharmaceuticals, 2008, 51, 369-373; Tang et. al, Nuclear Medicine and Biology, 2003, 30, 509-512.) " [F-18]fluoromethionine (2) (Neal et. al, Journal Labeled Compounds and 10 Radiopharmaceuticals, 2005, 51, 557-368.) " [F-18]fluoroalanine (3) (Yang et al., Journal of Drug Targeting, 1993, 1, 259 267.) " O-(2-deoxy-2-[F-18]fluoro-D-glucopyranosyl)-L-serine (4), 0-(2-deoxy-2-[F 18]fluoro-D-glucopyranosyl)-L-threonine (5) (Maschauer et. al, Journal 15 Labeled Compounds and Radiopharmaceuticals, 2005, 48, 701-719.) * F-18 labeled glutamic acid derivatives (6) (W02008052788) 0 0 0 F OH 18FOH 'F OH
NH
2 NH 2
NH
2 1 2 3 H H R' 0 0 R 0 HO OHO 18 F 0 OH HO OH
NH
2 RA NH 2 4 R = H 6 (RA, RB = H, 1 8 F, 1 8 F-alkyl, 1 8 F-alkoxy) 5 R = CH 3 20 Bourdier et. al synthesized 1 by a two-step / one-pot sequence using protected S-(2-bromoethyl)-L-homocysteine or S-(2-chloroethyl)-L-homocysteine. After fluorination using [F-18]fluoride/kryptofix/potassium carbonate at 100 *C, protecting groups were cleaved with 6N HCI at 100 *C. After neutralization with 6N NaOH and dilution with water, the mixture was analyzed by HPLC. The 25 authors found I to be unstable in aqueous solution. Repeating the synthesis WO 2011/060887 PCT/EP2010/006766 -4 method described by Tang et. al, the authors found the same instability of 1 in aqueous media. [F-18]fluoromethionine (2) was synthesized by Neal et. al by two-step / two-pot 5 method. After synthesis of [F-18]fluoromethyltosylate, the labeled intermediate was purified by solid-phase-extraction. After evaporation, alkylation of homocysteine afforded 14 % of [F-18]fluoromethionine (2) based on the labed intermediate [F-1 8]fluoromethyltosylate. io The synthesis of [F-18]fluoroalanine (3) by a two-step / two-pot sequence was described by Yang at. al. Tosylserine N-Boc methyl ester was treated with [F 18]fluoride/kryptofix/potassium carbonate in acetonitrile at 100 "C. The labeled intermediate was passed through a silica gel column and the solvent was evaporated. The protecting groups were cleaved using 2N HCI at 100 *C. After 15 neutralization with 2N NaOH, the mixture was passed through a C18 cartridge and diluted with water. O-(2-deoxy-2-[F-18]fluoro-D-glucopyranosyl)-L-serine (4) and O-(2-deoxy-2-[F 18]fluoro-D-glucopyranosyl)-L-threonine (5) were synthesized by Maschauer et 20 al. by F-18 glycosylation of protected amino acids. Peracetylated [F-18]FDG was used a prosthetic group. The synthesis sequence started with F-18 fluorination of (1,3,4,6-tetra-O-acetyl-2-O-trifluormethanesulfonyl-p-d mannopyranose). The protected [F-18]FDG derivative was purified by semi preparative HPLC. BF 3 etherate and Fmoc-protected serine or threonine was 25 added. After heating at 80 *C, the crude product mixture was purified by a second semi-preparative HPLC. Finally, protecting groups were cleaved in a third reaction vessel. F-18 labeled glutamic acid derivatives have been disclosed in W02008052788. 30 High uptake of the tracers was found in several tumor cell lines. 4-(3-[F-18]fluoropropyl)-glutamic acid was prepared in a two-pot sequence: 1) [F-18]fluorination of N-Boc 4-(3bromopropyl)-glutamic acid dimethyl ester; 2) solid-phase purification on silica gel; 3) purification by preparative reversed WO 2011/060887 PCT/EP2010/006766 -5 phase HPLC; 4) solid-phase-extraction on C18 silica gel; 5) deprotection using 4N HCI; 6) Neutralization using 2N NaOH. PROBLEM TO BE SOLVED 5 However, for a routine clinical use of a [ 1 8F] labeled glutamic acid derivative, a reliable and robust manufacturing process is needed, that is compliant with compliant with Good Manufacturing Practices (GMP) requirements and provides a stable injectable solution (isotonic, neutral pH) of the radiotracer. In face of the short half-live of [ 1 8F] (110 min), the process has to provide the radiolabeled 10 tracer in high radiochemical yield within short synthesis time (preferably less then 60 min).
[
18 F] labeled glutamic acid derivatives of Formula I have two stereo centers. 0 0 HO OH 18F,X NH 2 A method for manufacturing of such compounds has to assure, that the reaction 15 conditions of the method don't lead to a significant degree of epimerization at one or both stereocenters. The problem to be solved by the present invention was to provide a robust and reliable one-pot process for the manufacturing of an injectable formulation of 20 [1F] labeled glutamic acid derivatives with isomeric purity of greater than 90 %. Remote controlled synthesizers for [ 1 8 F] labeling should be adaptable to this process to allow a GMP compliant manufacturing of the ratio tracer. SUMMARY OF THE INVENTION 25 * The present invention provides a method for production of radiolabeled compound of Formula I and suitable salts of an inorganic or organic acid thereof, hydrates, complexes, esters, amides, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, adjuvant or excipient. 30 The method comprises the steps of: WO 2011/060887 PCT/EP2010/006766 -6 - Radiofluorination of compound of Formula I to obtain compound of Formula IlIl, - Cleavage of the protecting groups of compound of Formula III to obtain compound of Formula I, 5 - Purification and formulation of compound of Formula I by solid-phase extraction to obtain an injectable solution of compound of Formula I wherein 0 0 0 0 0 0 RLO O-R 2 RLO O-R 2 HO OH LG'X HN'R 3 OF"X HNsR3 1 8 F X NH 2 11 ~111 10 9 The present invention provides compounds of Formula Ila, lIb, lic or lid which are precursors (starting material) suitable for the manufacturing process to obtain compounds of Formula la, Ib, Ic or Id. 0 The present invention also provides compounds of Formula I with isomeric purity of greater than 90 %. 15 9 The present invention also provides compositions comprising a radiolabeled compound of Formula I, la, Ib, Ic or Id or suitable salts of an inorganic or organic acid thereof, hydrates, complexes, esters, amides, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, adjuvant or excipient. 20 * The present invention also provides a kit for preparing a radiopharmaceutical preparation by the herein described process, said kit comprising a sealed vial containing a predetermined quantity of the compound of Formula 11, Ila, lIb, lic or lid. 25 FIGURES Figure 1 Scheme of the ,Eckert&Ziegler modular lab" (Adopted from Eckert&Ziegler Modular Lab software).
WO 2011/060887 PCT/EP2010/006766 -7 Figure 2 Radio-TLC (silica, n-butanol / acetic acid / water / ethanol 12 / 3 / 5 i 1.5). Figure 3 Radio-TLC (silica, n-butanol / acetic acid / water / ethanol 12 / 3 / 5 / 1.5). 5 Figure 4 Radio-TLC (silica, n-butanol / acetic acid / water / ethanol 12 / 3 / 5 /1.5). Figure 5 Radio-TLC (silica, n-butanol / acetic acid / water / ethanol 12 / 3 / 5 / 1.5). Figure 6 Scheme of the ,,GE tracerlab FX" (Adopted from GE Tracerlab io software). Vial 14 was directly connected with the mixing vessel (the HPLC part of the module was not used). Figure 7 Scheme of the ,,GE tracerlab FX" (Adopted from GE Tracerlab software). 15 Figure 8 Derivatization HPLC (Chromolith Speed ROD, 50*4.6 mm, 5 pm, Merck; 0-95% acetonitrile in 10 mM phosphate buffer (pH 7.4); 2 mL/min); Example 8a, Table 1, entry 5; top: Radioactivity signal of (2S,4S)-4-(3 [1F]Fluoropropyl)-glutamic acid; bottom: co-elution, UV detection (340 nm) of 1 9 F reference (2S,4S)-4-(3-Fluoropropyl)-glutamic acid 20 Figure 9 Derivatization HPLC (Luna 5p C18(2), 250*4.6mm, 5p, Phenomenex; 12% acetonitrile in 10 mM phosphate buffer pH 7.4; 1.2 mL/min); Radioactivity signal; Ia: (2S,4S)-4-(3-[ 18 F]Fluoropropyl)-glutamic acid; 1 b: (2S,4R)-4-(3-[1 8 F]Fluoropropyl)-glutamic acid Figure 10 Determination of identity, radiochemical purity and ratio of 25 diastereoisomers by HPLC (Hypercarb column [100*4.6 mm, 7p, Thermo Scientific] with 2% acetonitrile in water + 0.1% TFA); A) (2S,4S)-4-(3
[
18 F]Fluoropropyl)-glutamic acid (1a) detected by radioactivity detector; B) reference (2S,4S)-4-(3-[1 9 F]Fluoropropyl)-glutamic acid (1a) detected by Corona detector; C) reference (2S,4R)-4-(3-[ 1 9 F]Fluoropropyl)-glutamic acid detected by 30 Corona detector(1b); D) blank run of buffer, detection by Corona Figure 11 Determination of radiochemical purity and ratio of diastereoisomers by HPLC (Hypercarb column [100*4.6 mm, 7p, Thermo Scientific] with 2% acetonitrile in water + 0.1% TFA, radioactivity detector).
WO 2011/060887 PCT/EP2010/006766 -8 Results from Example 10b). a) Table 2, entry 6: ratio (2S,4S)-4-(3 [1 8F]Fluoropropyl)-glutamic acid (1a) / (2S,4R)-4-(3-[18F]Fluoropropyl)-glutamic acid (1b) > 98/2; b) Table 2, entry 10: ratio 1a/1b = 95/5; c) Table 2, entry 13: ratio la/lb = 92/8; d) Table 2, entry 16: ratio la/lb = 82/18; e) Table 2, entry 5 11: ratio 1a/1b = 60/40; f) Table 2, entry 17: ratio 1a/1b = 50/50. Figure 12 Derivatization HPLC (Chromolith Speed ROD, 50*4.6 mm, 5 pm, Merck; 0-95% acetonitrile in 10 mM phosphate buffer (pH 7.4); 2 mL/min); Example 14, Radioactivity signal of (2S,4S)-4-(6-[ F]Fluorohexyl)-glutamic acid. 10 DESCRIPTION OF THE INVENTION In a first aspect the present invention is directed to a method for producing compound of Formula I 0 0 HO OH 1 F.X NH2 151 15 comprising the steps of: Step 1: Synthesizing radiolabeled compound of Formula III by reacting compound of Formula II with a F-18 fluorinating agent, 0 0 0 0 RLO
O-R
2 X NR 3
R
4 RLO
O-R
2 LG 18 FX NR 3
R
4 20 Step 2: Cleavage of the protecting groups of compound of Formula III to obtain compound of Formula I, Step 3: Purification and formulation of compound of Formula I wherein: 25 X is selected from the group comprising a) bond, WO 2011/060887 PCT/EP2010/006766 -9 b) branched or non-branched (C2-C1O)alkyl, c) branched or non-branched (C2-C1O)alkoxy, d) branched or non-branched (C3-C10)alkenyl, e) branched or non-branched (C3-C1O)alkynyl, 5 f) [(CH 2 )n-O]m-(CH 2 )o, and g) O-[(CH 2 )n-O]m-(CH 2 )o; n = 2-6, preferably n = 2 or 3; m = 1-3, preferably m = 1 or 2; o = 2-6, preferably o = 2 or 3; 10 R1 and R2 are carboxyl-protecting groups and wherein carboxyl-protecting group is independently from each other selected from a) branched or non-branched (C 1
-C
6 )alkyl, b) benzyl, and c) allyl; 15 R 3 and R 4 are independently from each other selected from the group comprising: a) hydrogen, b) an amine-protecting group or c) the group NR 3
R
4 is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl (phthalimido) or 20 an azido group. Formulas I, 11 and IlIl encompass single isomers, tautomers, diastereomers, enantiomers, mixtures thereof and suitable salts thereof. 25 In a preferred embodiment, X is selected from the group comprising a) a bond, b) branched or non-branched (C3-C8)alkyl, c) branched or non-branched (C2-C8)alkoxy, d) branched or non-branched (C3-C8)alkenyl, 30 e) branched or non-branched (C3-C8)alkynyl, f) [(CH 2 )n-O]m-(CH 2 )o, and g) 0-[(CH 2 )n-O1m-(CH 2 )o. In a more preferred embodiment, X is WO 2011/060887 PCT/EP2010/006766 -10 branched or non-branched (C3-C8)alkyl and even more preferably (C3-C6)alkyl. In a preferred embodiment, carboxyl-protecting group is Methyl, Ethyl, Propyl, Butyl, t-Butyl, or allyl. In a more preferred embodiment, carboxyl-protecting 5 group is a) methyl, b) ethyl, c) tert-butyl or d) allyl. 10 Preferably, R and R2 are independently from each other methyl, ethyl or tert butyl. Amine-protecting group is Carbobenzyloxy (Cbz), p-Methoxybenzyl carbonyl (Moz or MeOZ), tert-Butyloxycarbonyl (BOC), 9-Fluorenylmethyloxycarbonyl 15 (FMOC), Benzyl (Bn), p-Methoxybenzyl (PMB), 3,4-Dimethoxybenzyl (DMPM), Triphenylmethyl, p-methoxyphenyl (PMP), Trityl, Methoxytrityl, 1,3-dioxo-1,3 dihydro-2H-isoindol-2-yl (phthalimido) or an azido group. In a preferred embodiment, R 4 is hydrogen and R 3 is selected from the group comprising: 20 a) tert-Butyloxycarbonyl (BOC), b) Trityl and c) Methoxytrityl. LG is a leaving group. 25 In a preferred embodiment, LG is selected from the group comprising: a) Halogen and b) sulfonate. Halogen is chloro, bromo or iodo. Preferably, Halogen is bromo or chloro. 30 Sulfonate is Methylsulfonyloxy, Trifluoromethylsulfonyloxy, (4 Nitrophenyl)sulphonyloxy, Nonafluorobutylsulfonyloxy or (4- WO 2011/060887 PCT/EP2010/006766 - 11 Methylphenyl)sulfonyloxy. Preferably, Sulfonate is (4-Nitrophenyl)sulphonyloxy, Nonafluorobutylsulfonyloxy or (4-Methylphenyl)sulfonyloxy. Compounds obtained by invention method are selected from but not limited to 0 0 HO OH
-
NH
2 5 F (2S,4S)-4-3-[F-18]fluoropropyl}-glutamic acid, and 0 0 HO) 2 OH - NH 2 (2S,4S)-4-{3-[F- 1 8]fluorohexyl}-glutamic acid. Step 1 comprises a straight forward fluoro labeling reaction from compounds of 1o Formula Il for obtaining compound of formula Ill. The radiolabeling method for obtaining compound of formula IlIl comprises the step of reacting a compound of formula II with a F-18 fluorinating agent comprising a [F-18]fluoride derivative for obtaining a compound of formula Ill. In a preferred embodiment, the (F-18]fluoride derivative is 4,7,13,16,21,24-Hexaoxa-1,10 is diazabicyclo[8.8.8]-hexacosane K[F-18]F (crownether salt Kryptofix K[F-18]F), K[F 18]F, H[F-1 8]F, KH[F-1 8]F 2 , Cs[F-1 8]F, Na[F-1 8]F or tetraalkylammonium salt of [F 18]F (e.g.[F-1 8]tetrabutylammonium fluoride). More preferably, the fluorination agent is K[F-18]F, H[F-18]F, [F-18]tetrabutylammonium fluoride, Cs[F-18]F or KH[F-18]F 2 , most preferably K[F-18], Cs[F-18]F or [F-18]tetrabutylammonium 20 fluoride. The radiofluorination reactions are carried out in acetonitrile, dimethylsulfoxide or dimethylformamide or a mixture thereof. But also other solvents can be used which are well known to someone skilled in the art. Water and/or alcohols can 25 be involved in such a reaction as co-solvent. The radiofluorination reactions are WO 2011/060887 PCT/EP2010/006766 -12 conducted for less than 60 minutes. Preferred reaction times are less than 30 minutes. Further preferred reaction times are less than 15 min. This and other conditions for such radiofluorination are known to experts (Coenen, Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions, (2006), in: 5 Schubiger P.A., Friebe M., Lehmann L., (eds), PET-Chemistry - The Driving Force in Molecular Imaging. Springer, Berlin Heidelberg, pp.15-50). Step 2 comprises the deprotection of compound of formula IlIl to obtain compound of formula I (cleavage). Reaction conditions are known or obvious to io someone skilled in the art, which are chosen from but not limited to those described in the textbook Greene and Wuts, Protecting groups in Organic Synthesis, third edition, page 494-653, included herewith by reference. Preferred reaction conditions are addition of an acid and stirring at 0 *C-180 C; addition of an base and heating at 0 OC-1 80 0C; or a combination thereof. 15 Preferably the step 1 and step 2 are performed in the same reaction vessel. Step 3 comprises the purification and formulation of compound of formula I by solid-phase-extraction. Preferably solid-phase-extraction cartridges or column 20 can be used. Suitable solid phases for trapping of compound of formula I and elution of compound of formula I from the solid phase by aqueous buffers are chosen from but not limited to cation exchange resins (e.g. Waters MCX), Oasis HLB, Hydrophilic interaction liquid chromatography (HILIC) phases (e.g. Sequant Zic-Hilic). Additionally, compound of formula I can purified by passing 25 through solid phases chosen from but not limited to silica gel, RP silica gel, (Cl C18) silica gel, alumina, polystyrene-divinylbenzene copolymer (HR-P), hypercarb. In a preferred embodiment, the method is carried out by use of a module 30 (review: Krasikowa, Synthesis Modules and Automation in F-18 labeling (2006), in: Schubiger P.A., Friebe M., Lehmann L., (eds), PET-Chemistry - The Driving Force in Molecular Imaging. Springer, Berlin Heidelberg, pp. 289-316) which WO 2011/060887 PCT/EP2010/006766 -13 allows an automated synthesis. More preferably, the process is carried out by use of an one-pot module. Formulas I, I and Ill encompass suitable salts of an inorganic or organic acid 5 thereof, hydrates, complexes, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, adjuvant or excipient. In a second aspect the present invention is directed to a fully automated and/or remote controlled method for production of compound of Formula I. 10 In a preferred embodiment this method is a fully automated process, that provides a formulation of Formula I for the use of administration (injection) into human. Compound of formula I is disclosed above in the first aspect. 15 In a third aspect the present invention is directed to a method for obtaining compound of Formula I with isomeric purity of greater than 90 %, more preferably greater than 95 %. Compound of formula I is disclosed above in the first aspect. 20 In a fourth aspect the present invention is directed to compounds of Formula Ila, llb, lIc or lid independently from each other o o 0 0 R 0R R 0 R LG1"X" NR R 4X"
NR
3
R
4 Ila lib o o 0 0 R O O. R 2"R O O '-10R r2 X" NRR4" NY 4" LG""X N R LG"""" iR" lic or lid WO 2011/060887 PCT/EP2010/006766 - 14 wherein: X" is selected from the group comprising a) branched or non-branched (C2-C10) alkyl, b) branched or non-branched (C2-C10) alkoxy, 5 c) branched or non-branched (C3-C10) alkenyl with the proviso that LG is not attached to a sp2 hybridized carbon atom, d) ,branched or non-branched (C3-C10) alkynyl, with the proviso that LG is not attached to a sp hybridized carbon atom, e) [(CH 2 )n--O1m-(CH 2 )o-, and o f) 0-[(CH 2 )n-O]m--(CH 2 )o" wherein n" 2-6, preferably n" = 2 or 3, m"= 1-3, preferably m" = 1 or 2, o"= 2-6, preferably o" = 2 or 3, 15 R" and R2" are carboxyl-protecting groups and wherein carboxyl-protecting group is independently from each other selected from a) branched or non-branched (C 1
-C
6 )alkyl, b) benzyl, and c) allyl; 20 R 3 " and R4" are independently from each other selected from the group comprising: a) hydrogen, b) an amine-protecting group or c) the group NR 3
R
4 " is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-y (phthalimido) or 25 an azido group. Formula Ila, lib, lIc and lid encompass single isomers, tautomers, and suitable salts of an inorganic or organic acid thereof, hydrates, complexes, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, 30 adjuvant or excipient. In a preferred embodiment, X" is selected from the group comprising a) branched or non-branched (C3-C6)alkyl, WO 2011/060887 PCT/EP2010/006766 -15 b) branched or non-branched (C7-C10)alkyl, c) branched or non-branched (C2-C8)alkoxy, d) branched or non-branched (C3-C8)alkenyl, with the proviso that LG is not attached to a sp2 hybridized carbon atom, 5 e) ,branched or non-branched (C3-C8) alkynyl, with the proviso that LG is not attached to a sp hybridized carbon atom, f) [(CH 2 )n'--Olm--(CH 2 )o-, and g) O-[(CH 2 )n'-O]m--(CH 2 )o". io In a more preferred embodiment, X" is branched or non-branched (C3-C8)alkyl, preferably (C3-C6)alkyl. In an even more preferred embodiment, X" is propyl. Is In a preferred embodiment, carboxyl-protecting group is Methyl, Ethyl, Propyl, Butyl, t-Butyl or Allyl. In a more preferred embodiment, carboxyl-protecting group is a) methyl, b) ethyl, 20 c) tert-butyl or d) allyl. Preferably, R 1 and R2" are independently from each other methyl, ethyl or tert butyl. 25 Amine-protecting group is Carbobenzyloxy (Cbz), p-Methoxybenzyl carbonyl (Moz or MeOZ), tert-Butyloxycarbonyl (BOC), 9-Fluorenylmethyloxycarbonyl (FMOC), Benzyl (Bn), p-Methoxybenzyl (PMB), 3,4-Dimethoxybenzyl (DMPM), Triphenylmethyl, p-methoxyphenyl (PMP) , Trityl, Methoxytrityl, 1,3-dioxo-1,3 dihydro-2H-isoindol-2-yl (phthalimido) or an azido group. 30 In a preferred embodiment, R4" is hydrogen and R 3 is selected from the group comprising: a) tert-Butyloxycarbonyl (BOC), b) Trityl and WO 2011/060887 PCT/EP2010/006766 -16 c) Methoxytrityl. LG" is a leaving group. In a preferred embodiment, LG" is selected from the group comprising: 5 a) Halogen and b) sulfonate. Halogen is chloro, bromo or iodo. Preferably, Halogen is bromo or chloro. Sulfonate is Methylsulfonyloxy, Trifluoromethylsulfonyloxy, (4 Nitrophenyl)sulphonyloxy, Nonafluorobutylsulfonyloxy or (4 io Methylphenyl)sulfonyloxy. Preferably, Sulfonate is (4-Nitrophenyl)sulphonyloxy, Nonafluorobutylsulfonyloxy or (4-Methylphenyl)sulfonyloxy. Preferably, the compounds of fourth aspect are directed to compounds of formula Ila. 15 Preferably, the compounds of fourth aspect are directed to compounds of formula lib. Preferably, the compounds of fourth aspect are directed to compounds of formula lIc. Preferably, the compounds of fourth aspect are directed to compounds of 20 formula lId. Invention compounds Ila are selected from but not limited to 0 0 Hac O OCHa ), HN 1 O 00 cH 3 0S0O CH 3 1 5
R
WO 2011/060887 PCT/EP2010/006766 -17 0 0 HC 0 O CH 3 HN 0 o CH 3 I s=OCCH3 O=S= CH 3 15 R
H
3 C> E )P HN O H0 0 H 3 o cH, I CH, 0=S=0
CH
3 15 R wherein p = 1-4 and 5
R
5 is selected from the group comprising a) optionally substituted branched or non-branched alkyl, and b) optionally substituted aryl or heteroaryl. 10 In a preferred embodiment, R 5 is selected from the group comprising a) methyl, b) trifluoromethyl, c) p-methylphenyl, d) nitrophenyl, 15 e) bromophenyl and f) nonafluorobutyl. A more preferred compound of Formula Ila is: Di-tert-butyl (2S,4S)-N-(tert-butoxyca rbonyl)-4-[3-(mesyloxy])propy]-g lutamate WO 2011/060887 PCT/EP2010/006766 -18 CH 0 0 H 3 c>K 4 2 ,-CH 3
H
3 O O CH 3 HN 0 O CH3 0==0 CH 3
CH
3 Another more preferred compound of Formula Ila is: Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propy]-glutamate CH3 0 0 CH 3 H> 4 2 CH 3
H
3 0 0 H 3 HN 0 0 CH 3 =CHC 5
OH
3 Another more preferred compound of Formula Ila is: Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonyl]oxy}propyl)-glutamate 10 CH3 0 0 CH 3 Ha> 3 4 2 C 3 3 3C O CH 3 HN 0 O CH3 0 "1< OH 3 O=S=0
CH
3
NO
2 Another more preferred compound of Formula Ila is: WO 2011/060887 PCT/EP2010/006766 -19 o 0 H3C 2 'CH 3 0 0' HN 0 0
CH
3
H
3 C OH 3 Invention compounds lib are selected from but not limited to O o H3C' O O'CH 3 )p HN O O CH 1<CH 3 O=S=O OH 3 15 R o 0
H
3 C 0 0 CH 3 )p HN 0 0 CH o>CH O=S=0
CH
3 15 R HC 0 CH
H
3 C 0 O CH 3 )p HN_ 0 o
CH
3 )CH3 O=s=O CH, 3 15 5 R wherein p = 1-4 and
R
5 is selected from the group comprising to a) optionally substituted branched or non-branched alkyl, and b) optionally substituted aryl or heteroaryl. In a preferred embodiment, R 5 is selected from the group comprising a) methyl, WO 2011/060887 PCT/EP2010/006766 -20 b) trifluoromethyl, c) p-methylphenyl, d) nitrophenyl, e) bromophenyl and 5 f) nonafluorobutyl. A more preferred compound of Formula lib is: Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate
H
3
C>J,
3 4 2 CH
H
3 C 0 0 CH 3 HN 0 O CH 3 O CH o=S=O CH 3
CH
3 10 Another more preferred compound of Formula lib is: Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-[3-(tosyIoxy)propy]-glutamate H3CH 3 0 O CH HaC 4 2 AC 3 HC 0 O CH 3 HN 0 SC
H
3 )<CH O=s=O
CH
3
CH
3 15 Another more preferred compound of Formula Ilb is: Di-tert-butyl(2S,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonyl]oxy}propyl)-glutamate WO 2011/060887 PCT/EP2010/006766 -21 H CH3 O O CH3 C H3C> 4 2 3CH 3
H
3 C 0 CH 3 HN 0 0 CH 3 I )<CH3 OS=0
CH
3
NO
2 Invention compounds lic are selected from but not limited to O 0
H
3 CsO O CH 3 )p HN TO 0o0 CH3 CH O=S=O CH 3 R 0 0
H
3 C'1 0 O'CH 3 ) HN TO O CH S0 0 CH O)=s=O CH, 3 15 5 R
H
3 CH3 O CH O 3C 0 YO CH3 ), HN O 0 0 CH 3 IO CH O=S=0 CH 3 15 R wherein p = 1-4 and 10 R 5 is selected from the group comprising a) optionally substituted branched or non-branched alkyl, and WO 2011/060887 PCT/EP2010/006766 - 22 b) optionally substituted aryl or heteroaryl. In a preferred embodiment, R 5 is selected from the group comprising a) methyl, 5 b) trifluoromethyl, c) p-methylphenyl, d) nitrophenyl, e) bromophenyl and f) nonafluorobutyl. 10 A more preferred compound of Formula lic is: Di-tert-butyl (2R,4S)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate CH3 0 0 CH 3
H
3 C 0 - 0 OCH 3 HN 0 0OCH3 o O)CH 3 O=S=0 CHH 3
CH
3 15 Another more preferred compound of Formula llc is: Di-tert-butyl (2R,4S)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propy]-glutamate CH 0 0 CH 3 H3> 3 4 2 C
H
3 C 0 O CH 3 HN 0 O0 CH3 0=3=0 OH 3 '3
CH
3 Another more preferred compound of Formula lIc is: 20 Di-tert-butyl (2R,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonyl]oxy}propyl)-glutamate WO 2011/060887 PCT/EP2010/006766 -23 H 3
CCH
3 04 O jCH
H
3 C 0 CH 3 HN 0 O CH 0 0CH O)=s~=O CH 3
NO
2 Invention compounds lid are selected from but not limited to o 0 H3CsO O-0CH 3 )p HN rO O CH )CH =S=OCH 3 15 R 0 0 HC 0 0 CH 3 )p HN O 0 0 0~ CH3 CH O=S=O CH3 R H3C 0
CH
3
H
3 C 0 O CH 3 ), HN O 0 CH O CH O=s=O CH 3 15 5 R wherein p = 1-4 and
R
5 is selected from the group comprising 10 a) optionally substituted branched or non-branched alkyl, and b) optionally substituted aryl or heteroaryl.
WO 2011/060887 PCT/EP2010/006766 - 24 In a preferred embodiment, R 5 is selected from the group comprising a) methyl, b) trifluoromethyl, 5 c) p-methylphenyl, d) nitrophenyl, e) bromophenyl and f) nonafluorobutyl. 10 A more preferred compound of Formula lid is: Di-tert-butyl (2R,4R)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate H3CH3 O O CH3 HC> 4 2 O CH
H
3 C 0 0 CH H Oy 3 S0 O CH O=' 1=0 CHC,3
CH
3 Another more preferred compound of Formula lid is: 15 Di-tert-butyl (2R,4R)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propy]-glutamate
H
3 cCH 3 0 4 2 CH HaC 4 2 ACH 3
H
3 C 0 0 CH 3 HN 0 0 O CH3 IO CH O=S=0
CH
3
CH
3 Another more preferred compound of Formula lid is: Di-tert-butyl (2R,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) 20 sulfonyl]oxy}propyl)-glutamate WO 2011/060887 PCT/EP2010/006766 -25 CH 0 0 CH,
H
3
C>
3 4 2 CH
H
3 C 0 . CH3 HN O Y 0 CH 3 )YCH3 0=S=O
CH
3
NO
2 In a fifth aspect the present invention is directed to compounds of Formula la, Ib, Ic or Id independently from each other 5 O 0 0 0 HO OH HO OH 18 F-X' NH2 1F 1 X NH2 la lb O 0 0 0 HO OH HO OH 18 FX' NH2 18 FX' NH2 Ic ,or Id wherein: 10 X' is selected from the group comprising a) branched or non-branched (C2-C1O)alkyl, b) branched or non-branched (C2-C10)alkoxy, c) branched or non-branched (C3-C10) alkenyl with the proviso that LG is not attached to a sp 2 hybridized carbon atom, 15 d) ,branched or non-branched (C3-C10) alkynyl, with the proviso that LG is not attached to a sp hybridized carbon atom, e) [(CH 2 )n'-O]m'-(CH 2 )o', and WO 2011/060887 PCT/EP2010/006766 - 26 f) 0-[(CH 2 )n-Om--(CH 2 )o'; n' = 2-6, preferably n' = 2 or 3; m'= 1-3, preferably m' = 1 or 2; o' = 2-6, preferably o' = 2 or 3; 5 Formulas Ila, Ib, Ic and Id encompass single isomers, tautomers, diastereomers, enantiomers, mixtures thereof and suitable salts of an inorganic or organic acid thereof, hydrates, complexes, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, adjuvant or excipient. 10 In a preferred embodiment, X' is selected from the group comprising a) branched or non-branched (C3-C6)alkyl, b) branched or non-branched (C7-C10)alkyl, 15 c) branched or non-branched (C2-C8)alkoxy, d) branched or non-branched (C3-C8)alkenyl, with the proviso that LG is not attached to a sp 2 hybridized carbon atom, e) ,branched or non-branched (C3-C8) alkynyl, with the proviso that LG is not attached to a sp hybridized carbon atom, 20 f) [(CH 2 )n'-O]m.-(CH 2 )o', and g) 0-[(CH 2 )n-O]m-(CH 2 )o'. In a more preferred embodiment, X' is branched or non-branched (C3-C8)alkyl, preferably (C3-C6)alkyl. 25 In an even more preferred embodiment, X' is propyl. Preferably, the compounds of fifth aspect are directed to compound of formula Ia. Preferably, the compounds of fifth aspect are directed to compound of formula 30 lb. Preferably, the compounds of fifth aspect are directed to compound of formula Ic. Preferably, the compounds of fifth aspect are directed to compound of formula WO 2011/060887 PCT/EP2010/006766 -27 Id. A preferred compound of Formula Ila is: (2S,4R)-4-(3-[ 18 F]fluorohexyl)-glutamic acid O 0 H t-4 2 HO OH ~ NH 2 18 F 5 A preferred compound of Formula lb is: O 0 HO OH )p NH 2 wherein p is 1-4. 10 A more preferred compound of Formula Ib is: (2S,4R)-4-(3-[ 1 8 F]Fluoropropyl)-glutamic acid O 0 4 - 2 HO OH
NH
2 18 F A preferred compound of Formula Ic is: 0 0 HO OH ) NH 2 15 F WO 2011/060887 PCT/EP2010/006766 - 28 wherein p is 1-4. 5 A more preferred compound of Formula Ic is: (2R,4S)-4-(3-[ "F]Fluoropropyl)-glutamic acid O 0 HO 4 2 HO OH 1 F NH 2 18 F A preferred compound of Formula Id is: O 0 HO OH )p NH2 10 18 F wherein p is 1-4. 15 A more preferred compound of Formula Id is: (2R,4R)-4-(3-[ 16 F]Fluoropropyl)-glutamic acid O 0 4 2 HO P OH NH2 18 F In a sixth aspect the present invention is directed to compounds of Formula 20 lIla, Ilb, Ilic or Ilid independently from each other WO 2011/060887 PCT/EP2010/006766 -29 o 0 0 0 RO O-Rr R0 O-R 2 18 F X" NR R 4 18 F 'X"' NR 3
R
4 lila Ililb o 0 0 0 2" 1"1 2"' R 0 O-RR R 0 O-R 18F "' NR 3
R
4 1 F-X"' NR 3
R
4 lic or lild wherein: X.' is selected from the group comprising 5 a) branched or non-branched (C2-C1O)alkyl, b) branched or non-branched (C2-C1O)alkoxy, c) branched or non-branched (C3-C1O) alkenyl with the proviso that 1F is not attached to a sp2 hybridized carbon atom, d) ,branched or non-branched (C3-C1O) alkynyl, with the proviso that 1F is not 10 attached to a sp hybridized carbon atom, e) [(CH 2 )n--O]m-(CH 2 )o"', and f) 0-[(CH 2 )n"'-O]m"'-(CH 2 )o--; n= 2-6, preferably n.' = 2 or 3; m= 1-3, preferably m"' = 1 or 2; 15 o"' = 2-6, preferably o' = 2 or 3; R and R are carboxyl-protecting groups and wherein carboxyl-protecting group is independently from each other selected from a) branched or non-branched (C 1 -Ce)alkyl, b) benzyl, and 20 c) allyl; R 3 and R 4 are independently from each other selected from the group comprising: a) hydrogen, b) an amine-protecting group or WO 2011/060887 PCT/EP2010/006766 -30 c) the group NR 3
R
4 is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-y (phthalimido) or an azido group. Formulas lila, lib, Ilic and Hid encompass single isomers, tautomers, 5 diastereomers, enantiomers, mixtures thereof and suitable salts of an inorganic or organic acid thereof, hydrates, complexes, solvates and prodrugs thereof and optionally a pharmaceutically acceptable carrier, diluent, adjuvant or excipient. 10 In a preferred embodiment, X"' is selected from the group comprising a) branched or non-branched (C3-C6)alkyl, b) branched or non-branched (C7-C1O)alkyl, c) branched or non-branched (C2-C8)alkoxy, d) branched or non-branched (C3-C8)alkenyl, with the proviso that 1F is not 15 attached to a sp2 hybridized carbon atom, e) branched or non-branched (C3-C8) alkynyl, with the proviso that 18F is not attached to a sp hybridized carbon atom, f) [(CH 2 )ne'-O~m--(CH 2 )o", and g) O-[(CH 2 )n"'-O]m"-(CH 2 )o". 20 In a more preferred embodiment, X'" is branched or non-branched (C3-C8)alkyl, preferably, (C3-C6)alkyl. In an even more preferred embodiment, X'" is propyl. 25 In a preferred embodiment, carboxyl-protecting group is Methyl, Ethyl, Propyl, Butyl, t-Butyl, or allyl. In a more preferred embodiment, carboxyl-protecting group is a) methyl, b) ethyl, 30 c) tert-butyl or d) allyl. Preferably, R 1 " and R 2 are independently from each other methyl, ethyl or tert butyl.
WO 2011/060887 PCT/EP2010/006766 -31 Amine-protecting group is Carbobenzyloxy (Cbz), p-Methoxybenzyl carbonyl (Moz or MeOZ), tert-Butyloxycarbonyl (BOC), 9-Fluorenylmethyloxycarbonyl (FMOC), Benzyl (Bn), p-Methoxybenzyl (PMB), 3,4-Dimethoxybenzyl (DMPM), 5 Triphenylmethyl, p-methoxyphenyl (PMP) , Trityl, Methoxytrityl, 1,3-dioxo-1,3 dihydro-2H-isoindol-2-yl (phthalimido) or an azido group. In a preferred embodiment, R'" is hydrogen and R 3 " is selected from the group comprising: a) tert-Butyloxycarbonyl (BOC), io b) Trityl and c) Methoxytrityl. Preferably, the compounds of sixth aspect are directed to compounds of formula Ilia. 15 Preferably, the compounds of sixth aspect are directed to compounds of formula Ililb. Preferably, the compounds of sixth aspect are directed to compounds of formula 1lic. Preferably, the compounds of sixth aspect are directed to compounds of 20 formula Illd. 0 0 H3C' O .CH 3 HN 0 0
CH
3 H3C CH 3 In a seventh aspect the present invention is directed to a method for producing compound of Formula I wherein compound of Formula I is a compound of 25 Formula la, Ib, Ic or Id comprising the steps of: Step 1: Synthesizing radiolabeled compound of Formula Ill wherein compound of Formula Ill is a compound of Formula lila, Illb, IlIc or Illd by reacting compound of Formula II wherein compound of WO 2011/060887 PCT/EP2010/006766 - 32 Formula Il is a compound of Formula Ila, lib, lic or lid with a F-18 fluorinating agent, Step 2: Cleavage of the protecting groups of compound of Formula Ill wherein compound of Formula III is a compound of Formula Ilia, 5 Illb, Ilic or 1lid to obtain compound of Formula I wherein compound of Formula I is a compound of Formula Ia, Ib, Ic or Id , and Step 3: Purification and formulation of compound of Formula I wherein compound of Formula I is a compound of Formula Ia, Ib, Ic or Id io wherein Step 1, Step 2, and Step 3 are described in the first aspect, compound of Formula Ia, Ib, Ic or Id, compound of Formula lIla, lIb, lic or lid and compound of Formula Ilia, 1lib, Ilic or Illd as described in the fourth, fifth, and sixth aspects respectively. 15 Preferably the method is directed to compounds of formula Ia, Ila, and lila. Preferably the method is directed to compounds of formula Ib, lib, and 111b. Preferably the method is directed to compounds of formula Ic, lIc, and hi1d. Preferably the method is directed to compounds of formula Id, lId, and lild. 20 Preferred features and embodiments disclosed above are herein enclosed. In an eighth aspect the present invention is directed to a method for producing compounds of Formula I, Formula Ia, Formula lb, Formula Ic, or Formula Id as described in the first, second, third, fifth and seventh aspects , 25 wherein the F-18 fluorination reaction described in Step 1 is carried out at 0 0C - 160 *C, preferably at 0 0C - 140 0C, more preferably at 20 *C - 120 "C, even more preferably at 60 *C - 120 0C and even more preferably at 60 0C - 100 *C. Preferably the method is directed to compounds of formula Ia. 30 Preferably the method is directed to compounds of formula lb. Preferably the method is directed to compounds of formula Ic. Preferably the method is directed to compounds of formula Id.
WO 2011/060887 PCT/EP2010/006766 -33 More preferably, the method is automated and/or remote controlled. In a ninth aspect the present invention is directed to a method for producing compounds of Formula I, Formula la, Formula lb, Formula Ic, or Formula Id, 5 as described in the first, second, third, fifth and seventh aspects wherein the
[
1 8 F] fluorination agent used in Step 1 is generated from a base and [ 18 F]fluoride. Typically, [ 18 F]fluoride is trapped on an anion exchange resin and afterwards washed from the resin using a solution of the base into a reaction vessel. 10 Alternatively, [ 18 F]fluoride and the base can be mixed directly in the reaction vessel. The base can be an inorganic or organic base. Preferably, the base is selected from the group comprising: 15 a) a potassium salt, b) a caesium salt, c) a rubidium salt, d) a tetraalkyl ammonium salt, e) a phosphazene. 20 More preferably, the base is selected from the group comprising: a) a potassium salt, b) a caesium salt, c) a tetraalkyl ammonium salt. Even more preferably, the base is selected from the group comprising: 25 potassium carbonate, potassium bicarbonate, tripotassium phosphate, dipotassiLIm phosphate, monopotassium phosphate, potassium oxalate, potassium hydroxide, potassium mesylate, caesium carbonate, cesium bicarbonate, tetraalkyl ammonium hydroxide, tetraalkyl ammonium bicarbonate, tetraalkyl ammonium mesylate. 30 In a preferred embodiment, the ratio of the base and compound of Formula i or Formula Ila or Formula lib or Formula lic or Formula lid is greater than zero (>0) and equal or below 1 (51). More preferably, the ratio of the base and WO 2011/060887 PCT/EP2010/006766 -34 compound of Formula 11 or Formula Ila or Formula lib or Formula lic or Formula lid is greater than zero (>0) and is below 1 (<1). Preferably the method of ninth aspect is combined with the method of eighth 5 aspect. In a tenth aspect the present invention is directed to a method for producing compound of Formula I, Formula la, Formula Ib, Formula Ic or Formula Id, as described in the first, fifth, seventh eighth and ninth aspects wherein the 1o compound of Formula I, Formula la, Formula lb, Formula Ic or Formula Id has an isomeric purity of greater than 90%, preferably greater than 95%, more preferably greater than 98%. More preferably, the method is automated and/or remote controlled. 15 In an eleventh aspect the present invention is directed to a method for obtaining a formulation of compound of Formula I, Formula Ia, Formula Ib, Formula Ic or Formula Id, or mixture thereof as described in the first and fifth aspects, and invention is as well directed to a formulation of compound of Formula I, Formula la, Formula 1b, Formula Ic or Formula Id, or mixture thereof 20 wherein the formulation is a radiopharmaceutical formulation suitable for the administration into mammal. Optionally, the radiopharmaceutical formulation comprises additionally one or more physiologically acceptable vehicle or carrier and optional adjuvants and 25 preservatives known in the art such as water and/or inorganic salts, selected from but not limited to the group comprising sodium chloride, monosodium phosphate, disodium phosphate, trisodium phosphate, any pH adjusting agent known in the art 30 Optionally, the radiopharmaceutical formulation comprises additionally radiostabilizers selected from but not limited to the group comprising ascorbic acid and salts thereof, gentisic acid and salts thereof.
WO 2011/060887 PCT/EP2010/006766 -35 Optionally, the radiopharmaceutical formulation comprises additionally 0-20% ethanol, preferably 0-15% ethanol, more preferably 0-10% ethanol, even more preferably less than 5% ethanol. 5 The method for obtaining a formulation comprising compound of Formula I, Formula la, Formula lb, Formula Ic or Formula Id, or mixture thereof comprises the step of adding one or more physiologically acceptable vehicle or carrier, adjuvants or preservatives known in the art as listed above to a solution of compound of Formula I, Formula la, Formula Ib, Formula Ic or Formula Id, or 10 mixture thereof wherein the formulation is suitable for the administration into mammal. In a twelfth aspect the present invention is directed to a device for carrying out the method as described in first, second, third, seventh, eighth, ninth and 15 tenth aspects for producing compound of Formula 1, Formula la, Formula lb, Formula Ic or Formula Id as described in the first and fifth aspects and radiopharmaceutical formulation as described in eleventh aspect wherein the method is an automated and/or remote controlled method or process and the invention is as well directed to the use of such device for obtaining invention 20 compounds. Preferably, the method or process is an automated (optionally fully automated) and/or remote controlled method or process. The device of the present invention is a radiopharmaceutical synthesizer suitable for radiofluorinations. The device is a non-cassette type or a cassette 25 type synthesizers. Non-cassette type synthesizers are: GE Tracerlab FX, Eckert&Ziegler modular lab, Siemens Explora, Raytest SynChrom, Scintomics Hotbox. Cassette type synthesizers are: GE Tracerlab MX, GE Fastlab, IBA Synthera. The present invention is not limited to the mentioned synthesizers. The device of the present invention is a non-cassette type or a cassette-type 30 synthesizers suitable for radiofluorinations charactherised in that the device is carrying out the method as described in first, second, third, seventh, eighth, ninth and tenth aspects for producing compound of Formula I, Formula la, WO 2011/060887 PCT/EP2010/006766 -36 Formula Ib, Formula Ic or Formula Id as described in the first and fifth aspects and radiopharmaceutical formulation as described in eleventh aspect wherein the method is an automated and/or remote controlled method or process. 5 In a thirteenth aspect the present invention is directed to a Kit for producing of compound of Formula 1, Formula la, Formula lb, Formula Ic or Formula Id, as described in the first and fifth aspects and at least one sealed vial containing a compound of formula 11, Formula Ila, Formula lIb, Formula lic or Formula lid thereof. 10 Preferably, the Kit comprises predefined quantity of compound of Formula 11, Formula Ila, Formula llb, Formula lIc or Formula lid as described in the first and fifth aspects and one or more solid-phase extraction cartridges/columns for the purification of compound of Formula I, la, 1b, Ic or Id. 15 Preferably, the Kit comprises physiologically acceptable vehicle or carrier and optional adjuvants and preservatives, reagents suitable to perform the herein disclosed reactions and/or [ 18 F] labelling reagents. Furthermore, the kit may contain instructions for its use. 20 Optionally, the Kit comprises additionally one or more solid-phase-extraction cartridges or columns for purification of compound of Formula 1, Formula la, Formula Ib, Formula Ic or Formula Id as described in the first and fourth aspects, preferably, at least one solid-phase-extraction cartridge or column 25 based on cation-exchange material. Definitions If chiral centers or other forms of isomeric centers are present in a compound 30 according to the present invention, all forms of such stereoisomers, including enantiomers and diastereoisomers, are intended to be covered herein. Compounds containing chiral centers may be used as racemic mixture or as an enantiomerically enriched mixture or as a diastereomeric mixture or as a WO 2011/060887 PCT/EP2010/006766 -37 diastereomerically enriched mixture, or these isomeric mixtures may be separated using well-known techniques, and an individual stereoisomer maybe used alone. In cases in which compounds have carbon-carbon double bonds, both the (Z)-isomers and (E)-isomers as well as mixtures thereof are within the 5 scope of this invention. In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included. In the context of the present invention, preferred salts are pharmaceutically suitable salts of the compounds according to the invention. The invention also io comprises salts which for their part are not suitable for pharmaceutical applications, but which can be used, for example, for isolating or purifying the compounds according to the invention. Pharmaceutically suitable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulphonic is acids, for example salts of hy-drochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalene disul-phonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid. 20 Pharmaceutically suitable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium salts and potassium salts), alkaline earth metal salts (for example calcium salts and magnesium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 25 carbon atoms, such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, dietha-nolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, diben-zylamine, N methylmorpholine, arginine, lysine, ethylenediamine and N methylpiperidine. 30 The term halogen or halo refers to Cl, Br, F or 1. The term "C2-C1O alkyl", used herein on its own or as part of another group, refers to saturated carbon chains which may be straight-chain or branched, in particular to ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2,2 WO 2011/060887 PCT/EP2010/006766 -38 dimethylpropyl, 2 methylbutyl, 3 methylbutyl, n-hexyl, n-heptyl, n-octyl, n nonyl or n-decyl groups. Preferably, C2-C10 alkyl is C2-C6 alkyl or C7-C1O alkyl. C2 C6 alkyl is preferably C3-C6 alkyl. C7-C1O alkyl is preferably C7-C8 alkyl or C9 C10 alkyl. Preferably, C2-C6 alkyl is C3-C4 alkyl, C3 alkyl or C4 alkyl. 5 The term "C3-C6 cycloalkyl" used herein on its own or as part of another group, refers to a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. The term "C2-C10-alkoxy" used herein on its own or as part of another group, refers to an O-alkyl chain, in particular to ethoxy, n-propoxy, n-butoxy, n pentyloxy, n-hexyloxy, n-heptyloxy, n-octyloxy, n-nonyloxy or n-decyloxy group. 10 Preferably, C2-C10 alkoxyl is C2-C6 alkoxyl or C7-C10 alkoxyl. C2-C6 alkoxyl is preferably C3-C6 alkoxyl. C7-C10 alkoxyl is preferably C7-C8 alkoxyl or C9-C10 alkoxyl. The term "aryl" as employed herein by itself or as part of another group refers to phenyl or naphthyl groups, which themselves can be substituted with one, two is or three substituents independently and individually selected from but not limited to the group comprising halogen, nitro, formyl, acetyl, alkoxycarbonyl, cyano, nitrile, trifluoromethyl, (Cl-C3)alkylsulfonyl or (Cl-C3)alkyl. The term "heteroaryl" as employed herein by itself or as part of another group refers to monocyclic or bicyclic heteroaromatic groups containing from 5 to 10 20 ring atoms, wherein 1 or 2 atoms of the ring portion are independently selected from N, 0 or S, e.g. thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, indolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl etc. 25 As outlined above such "heteroaryl" may additionally be substituted by one or two substituents independently and individually selected from but not limited to the group comprising halogen, nitro, formyl, acetyl, alkoxycarbonyl, cyano, nitrile, trifluoromethyl, (C1-C3)alkylsulfonyl or (C1-C3)alkyl. The term "amine-protecting group" as employed herein by itself or as part of 30 another group is known or obvious to someone skilled in the art, which is chosen from but not limited to a class of protecting groups namely carbamates, amides, imides, N-alkyl amines, N-aryl amines, imines, enamines, boranes, N-P WO 2011/060887 PCT/EP2010/006766 -39 protecting groups, N-sulfenyl, N-sulfonyl and N-silyl, and which is chosen from but not limited to those described in the textbook Greene and Wuts, Protecting groups in Organic Synthesis, third edition, page 494-653, included herewith by reference. The amine-protecting group is preferably Carbobenzyloxy (Cbz), p 5 Methoxybenzyl carbonyl (Moz or MeOZ), tert-Butyloxycarbonyl (BOC), 9 Fluorenylmethyloxycarbonyl (FMOC), Benzyl (Bn), p-Methoxybenzyl (PMB), 3,4 Dimethoxybenzyl (DMPM), p-methoxyphenyl (PMP) or the protected amino group is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-y (phthalimido) or an azido group. 10 Carboxyl-protecting group is Methyl, Ethyl, Propyl, Butyl, t-Butyl, Allyl, Benzyl, 4 Methoxybenzyl or 4-Methoxyphenyl. The term "leaving group" as employed herein by itself or as part of another group is known or obvious to someone skilled in the art, and means that an atom or group of atoms is detachable from a chemical substance by a '5 nucleophilic agent. Examples are given e.g. in Synthesis (1982), p. 85-125, table 2 (p. 86; (the last entry of this table 2 needs to be corrected: "n
C
4
F
9
S(O)
2 -0- nonaflat" instead of "n-C 4 H9S(O) 2 -O- nonaflat"), Carey and Sundberg, Organische Synthese, (1995), page 279-281, table 5.8; or Netscher, Recent Res. Dev. Org. Chem., 2003, 7, 71-83, scheme 1, 2, 10 and 15 and 20 others). (Coenen, Fluorine-18 Labeling Methods: Features and Possibilities of Basic Reactions, (2006), in: Schubiger P.A., Friebe M., Lehmann L., (eds), PET Chemistry - The Driving Force in Molecular Imaging. Springer, Berlin Heidelberg, pp.15-50, explicitly: scheme 4 pp. 25, scheme 5 pp 28, table 4 pp 30, Fig 7 pp 33). 25 "Alkynyl" means a linear hydrocarbon radical of two to six carbon atoms or a branched hydrocarbon radical of three to 6 carbon atoms which radical contains at least one triple bond, e.g., ethynyl, propynyl, butynyl, pentyn-2-yl and the like. "Alkenyl" means a means a linear hydrocarbon radical of two to six carbon atoms or a branched hydrocarbon radical of three to 6 carbon atoms which 30 radical contains at least one double bond, e.g., ethenyl, propenyl, 1-but-3-enyl, and I-pent-3-enyl, and the like.
WO 2011/060887 PCT/EP2010/006766 -40 The term "purification" as employed herein has the objective to eliminate the excess of side product such as 1 8 F-Fluoride and to concentrate and trap the reaction product. Purification is carried out by by any method known to those in the art, suitable for radiotracer e.g. solid-phase-extraction cartridges or column. 5 The wording "automated and/or remote controlled device" refers to a device that is suitable for carrying out the radiosynthesis of a radiolabeled compound and maybe fully automated . The device comprises a reactor system, valves modules and a controller adapted to control the operation of said network. The term "Good manufacturing practice" or "GMP" is part of a quality system io covering the manufacture and testing of active pharmaceutical ingredients, diagnostics, foods, pharmaceutical products, and medical devices. GMPs are guidelines that outline the aspects of production and testing that can impact the quality of a product e.g. manufacturing processes are clearly defined and controlled. All critical processes are validated to ensure consistency and 15 compliance with specifications. Unless otherwise specified, when referring to the compounds of formula the present invention per se as well as to any pharmaceutical composition thereof the present invention includes all of the hydrates, salts, and complexes. 20 General synthesis of precursors for radiolabeling Precursors for alkyl-F-18 compounds of general formula I are e.g. tosylates, brosylates, nosylates, mesylates, triflates, nonaflates etc. (formula 1l) which can be synthesized from the respective hydroxy compounds according to methods 25 known in the art (J. March, Advanced Organic Chemistry, 4th ed. 1992, John Wiley & Sons, pp 352ff). More specifically, a hydroxy group being attached to a sp3 hybridized carbon atom can be converted to a leaving group by an activating agent like thionyl chloride (e.g. Organic and Biomolecular Chemistry; 4; 22; (2006); 4101 - 4112), phosphorus pentachloride (e.g. Bioorganic and 30 Medicinal Chemistry; 16; 6; (2008); 3309-3320), methanesulfonyl chloride (e.g. Organic and Biomolecular Chemistry; English; 4; 24; (2006); 4514 - 4525), carbon tetrachloride / triphenylphosphine (Tetrahedron: Asymmetry; English; WO 2011/060887 PCT/EP2010/006766 -41 19; 5; 2008; 577 - 583), hydrogen chloride (e.g. Russian Chemical Bulletin; English; 56; 6; 2007; 1119 - 1124), N-chloro-succinimide/ dimethylsulfide (e.g. Bioscience, Biotechnology, and Biochemistry 72; 3; (2008); 851 - 855), hydrogen bromide (e.g. Journal of Labeled Compounds and 5 Radiopharmaceuticals; 51; 1; (2008); 12 - 18), phosphorus tribromide (Journal of the American Chemical Society; 130; 12; (2008); 3726 - 3727), carbon tetrabromide / triphenylphosphine (e.g. Journal of the American Chemical Society; 130; 12; (2008); 4153 - 4157), N-bromo-succimide/SMe2 (e.g. Chemical Communications (Cambridge, United Kingdom); 1; (2008); 120 io 122), bromine / triphenylphosphine (e.g. Journal of the American Chemical Society; 130; 12; (2008); 4153 - 4157), N-bromo-succimide/SMe2 (e.g. Chemical Communications (Cambridge, United Kingdom); 1; (2008); 120 122), Br2/PPh3 (e.g. European Journal of Organic Chemistry; 9; (2007); 1510 1516), mesylchloride, tosylchloride, trifluormethylsulfonylchloride, nona 15 fluorobutylsulfonylchloride, (4-bromo-phenyl)sulfonylchloride, (4-nitro phenyl)sulfonylchloride, (2-nitro-phenyl)sulfonylchloride, (4-isopropyl phenyl)sulfonylchloride, (2,4,6-tri-isopropyl-phenyl)sulfonylchloride, (2,4,6 trimethyl-phenyl)sulfonylchloride, (4-tertbutyl-phenyl)sulfonylchloride, (4 methoxy-phenyl)sulfonylchloride, mesylanhydride, tosylanhydride, 20 trifluormethylsulfonylanhydride, nona-fluorobutylsulfonylanhydride, (4-bromo phenyl)sulfonylanhydride, (4-nitro-phenyl)sulfonylanhydride, (2-nitro phenyl)sulfonylanhydride, (4-isopropyl-phenyl)sulfonylanhydride, (2,4,6-tri isopropyl-phenyl)sulfonylanhydride, (2,4,6-trimethyl-phenyl)sulfonylanhydride, (4-tertbutyl-phenyl)su Ifonylan hydride, (4-methoxy-phenyl)sulfonylanhyd ride etc. 25 An additional method which is applicable to the synthesis of those alkyl chains R1 in formula 1-Ill which are interrupted by 1 or 2 oxygen atoms comprises the alkylation of hydroxy compounds by suitable bis(arylsulfonates) or bis(alkylsulfonates) bis(tosylates) and the like, e.g. bis(tosylates) TsO-(CH2)n OTs. 30 The synthesis of hydroxy compounds as starting materials for tosylates, brosylates, nosylates, mesylates, triflates, nonaflates etc. comprisesthe deprotection of OH-protecting groups. As one of the very versatile protecting WO 2011/060887 PCT/EP2010/006766 -42 groups might be mentioned the acetyl protecting group. Many others are known in the art, see e.g. T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd ed, 1999, John Wiley & Sons, pp 17ff). 5 The hydroxy compounds can alternatively be synthesized directly by those skilled in the art by e.g. hydroboration of corresponding vinylic compounds, reduction of carbonyl compounds, or alkylation of deprotonated homoglutamate derivatives with epoxides (R.C. Larock, Comprehensive Organic Transformations, VCH Publishers 1989, p. 479-582) or by direct p-oxidation of 1o carbonyl compounds via sulfonyloxaziridines (F. A. Davis et al., J. Org. Chem. 1984, 49(17), 3241-3243) or MoOPH (J. Marin et al., JOC 2002, 67, 8440 8449) e.g. at C5. L-Glutamic acid derivatives are referred to as (2S)-glutamic acid derivatives and 15 D-glutamic acid derivatives are referred to as (2R)-glutamic acid derivatives. Compounds of general formula lid can be synthesized as described in the examples 1,2,3 and 4 if instead of (2S) glutamic acid derivatives the corresponding (2R) glutamic acid derivatives are used. 20 Compounds of general formula lic can be synthesized as described in the example 12 if instead of (2S) glutamic acid derivative the corresponding (2R) glutamic acid derivative is used. Compounds of general formula Ic and compounds of general formula Id can be synthesized identical to the methods described in the examples 5, 6, 7, 8, 9, 10, 25 if compounds general formula lic or compounds of general formula lid are used instead of compounds of formula Ila as described in the examples. EXPERIMENTAL PART 30 General remarks The composition of "potassium carbonate/kryptofix solution" described in the Examples 6, 7, 8, 9, 13 is: 1 mg potassium carbonate and 5 mg kryptofix in 950 WO 2011/060887 PCT/EP2010/006766 - 43 pL acetonitrile and 50 pL water. 1 mg (7.24 pmol) potassium carbonate is added to the reaction if 1 mL of the solution is used (Example 6 and Example 7). 1.5 mg (10.9 pmmol) potassium carbonate are added to the reaction if 1.5 mL of the solution are used (Example 8 and Example 9). 5 Analytical methods for F-18 labeled compounds F-18 labeled compounds described in the examples herein have been analyzed by radio-TLC (thin-layer-chromatography) and HPLC. Radio-TLC have been performed using silica plates (Si 60F 254 , Merck) and a io solvent systems consisting of n-butanol / acetic acid / water / ethanol (12 / 3 / 5 / 1.5). For examples see Figures 2, 3, 4, 5. HPLC analysis have been performed using a Hypercarb column (100*4.6 mm, 7p, Thermo Scientific) with 2% acetonitrile in water + 0.1% TFA. For examples see Figure 9. Co-elution of the radiolabeled compounds with the corresponding 15 F-19 reference compounds was monitored using a Corona detector (ESA Biosciences). For examples see Figures 10, 11. HPLC analysis have been also performed using pre-column derivatization HPLC. 10 pL sample were mixed with 30 pL OPA-reagent (Fluoraldehyde T M o Phthalaldehyde Reagent Solution; Thermo Scientific). Mixing was done 20 manually or be means of the autosampler of the HPLC. The derivatized sample was analyzed on a C18 column: - Luna (5p C18(2), 250*4.6mm, 5p, Phenomenex); 12% acetonitrile in 10 mM phosphate buffer (pH 7.4); 1.2 mL/min; (For example see Figure 9) or: - Chromolith (Speed ROD, 50*4.6 mm, 5 pm, Merck); 0-95% acetonitrile in 10 25 mM phosphate buffer (pH 7.4); 2 mL/min (For examples see Figure 8 and 12). Co-elution of the radiolabeled compounds with the corresponding F-19 reference compounds was monitored using at 340 nM (characteristic wave length of "OPA-derivatives"). For example see Figure 8). 30 Example 1 Dimethyl (2S, 4S)-N-(tert-butoxycarbonyl)-4-[3 (mesyloxy)propyl]-g lutamate WO 2011/060887 PCT/EP2010/006766 -44 a) Dimethyl (2S,4S)-4-allyl-N-(tert-butoxvcarbonyl)-qlutamate o 0 HCO ,4 2 CH - HN O
CH
2 0 CH 3 H C CH 3 11.01 g (40 mmol) of dimethyl Boc-glutamate (Advanced Chemtech) were dissolved in 160 mL of tetrahydrofuran and cooled to -70 "C. 88 mL (88 mmol) 5 of a 1M solution of lithium bis(trimethylsilyl)amide in tetrahydrofuran were added dropwise at this temperature over a period of one hour, and the mixture was stirred at -70 *C for another 2 hours. 14.52 g (120 mmol) of allylbromide were then added dropwise, and after 2 h at this temperature, the cooling bath was removed and 200 mL of 2N aqueous hydrochloric acid and 400 mL of ethyl io acetate were added. The organic phase was separated off, washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate was concentrated. The crude product obtained in this manner was chromatographed in silica gel using a hexane/ethyl acetate gradient, and the appropriate fractions were combined and concentrated. 15 Yield: 3.3 g (26 %) MS (ESIpos): m/z = 316 [M+H]+ 1H-NMR (400MHz, CHLOROFORM-d): Shift [ppm]= 1.44 (s, 9H), 1.99 - 2.02 (m, 2H), 2.31 - 2.39 (m, 2H), 2.56 - 2.61 (m, 1H), 3.67 (s, 3H), 3.73 (s, 3H), 4.33 20 - 4.15 (m, 1H), 4.33 - 4.37 (m, 1H), 4.95 - 4.97 (m, 1H), 5.04 - 5.10 (m, 2H), 5.67 - 5.76 (m, 1H). b) Dimethyl (2S, 4S)-N-(tert-butoxycarbonyl)-4-(3-hydroxpropyl)-qluta mate o 0 H 3C,0 0,C H 3 HN 0 HO 0 CH 3
H
3 C COH WO 2011/060887 PCT/EP2010/006766 -45 3.15 g (10 mmol) of dimethyl (2S,4S)-4-allyl-N-(tert-butoxycarbonyl)-glutamate were dissolved in 50 mL of tetrahydrofuran and cooled in an ice-bath. Over a period of 20 minutes, 13.3 mL of 1 M diboran/tetrahydrofuran complex in tetrahydrofuran were added dropwise with ice-cooling and under nitrogen, and s the mixture was stirred on ice for 1 h and at room temperature overnight. 15 mL of 1 N aqueous sodium hydroxide solution and 13.3 mL of 30% aqueous hydrogen peroxide solution were then added dropwise. After 30 minutes, the mixture was diluted with water, the tetrahydrofuran was distilled off and the remaining aqueous solution was extracted with ethyl acetate. The organic phase 1o was separated off, washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate was concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient, and the appropriate fractions were combined and concentrated. Yield: 0.6 g (18%) 15 MS (ESIpos): m/z = 334 [M+H]+ 1H-NMR (600MHz, CHLOROFORM-d): Shift [ppm]= 1.44 (s, 9H), 1.47 - 1.98 (m, 6H), 2.51 -2.55 (m, 1H), 3.61 - 3.62 (m, 2H), 3.68 (s, 3H), 3.74 (s, 3H), 4.37 4.41 (m, 1H), 5.04 (d, 1H). 20 c) Dimethyl (2S,4S)-N-(tert-butoxycarbonyl)-4-[3-(m esyloxy)propyl-qluta mate o 0 H O. CH 3 HN 0 0 CH O=S~o H 3 C/ OH 3 6H 3 0.17 g (0.5 mmol) of dimethyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3 hydroxypropyl)-glutamate was dissolved in dichloromethane and cooled in an 25 ice-bath. After addition of 0.30 g (3 mmol) of triethylamine and 115 mg (1 mmol) of methanesulphonyl chloride, the mixture was stirred on ice for 2 h and then concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the appropriate fractions were combined and concentrated.
WO 2011/060887 PCT/EP2010/006766 - 46 Yield: 145 mg (70.5%) MS (ESipos): m/z = 412 [M+H]+ 1H-NMR (300MHz, CHLOROFORM-d): Shift [ppm]= 1.44 (s, 9H), 1.68 - 1.79 5 (m, 4H), 1.98-2.05 (m, 2H), 2.48-2.56 (m, 1H), 3.02 (s, 3H), 3.69 (s, 3H), 3.74 (s, 3H), 4.20-4.24 (m, 2H), 4.30-4.39 (m, 1H), 4.95-4.99 (m, 1H). Example 2 Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy) 10 propyl]- glutamate a) Di-tert-butyl (2S,4S)-4-allyl-N-(tert-butoxycarbonyl)-qlutamate
CH
3 O 0 CH
H
3 C>I. 3 2
H
3 C 0 C l- 3 HN 0
CH
2 0 CH
H
3 C
CH
3 26.96 g (75 mmol) of di-tert-butyl Boc-glutamate (Journal of Peptide Research 15 (2001), 58, 338) were dissolved in 220 mL of tetrahydrofuran (THF) and cooled to -70 *C. 165 mL (165 mmol) of a 1M solution of lithium bis(trimethylsilyl)amide in THF were added dropwise over a period of two hours at this temperature and the mixture was stirred at -70 *C for another 2 hours. 27.22 g (225 mmol) of allyl bromide were then added dropwise, and after 2 h at this temperature, the 20 cooling bath was removed and 375 mL of 2N aqueous hydrochloric acid and 1.25 L of ethyl acetate were added. The organic phase was separated off, washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate was concentrated. The crude product obtained in this manner was chromatographed in silica gel using a hexane/ethyl acetate gradient, and the 25 appropriate fractions were combined and concentrated. Yield: 15.9 g (53.1%) MS (ESIpos): m/z = 400 [M+H]+ WO 2011/060887 PCT/EP2010/006766 - 47 1H NMR (300 MHz, CHLOROFORM-d) d ppm 1.32-1.58 (m, 27H) 1.81-1.92 (m, 2H) 2.25-2.39 (m, 2H) 2.40-2.48 (m, 1H), 4.10-4.18 (m, 1H) 4.85-4.92 (d, 1H) 5.02-5.11 (m, 2H) 5.68-5.77 (m, 1H) 5 b) Di-tert-butyl (2 S,4S)-N-(tert-butoxvcarbonyl)-4-(3-hvd roxvpropyl)-qlutamate
H
3 "" 04 2 H QC 3
H
3 C 0 CH -HN O0 0 CH3 HO O CH3
H
3 C
CH
3 15,58 g (39 mmol) of di-tert-butyl (2S,4S)-4-allyl-N-(tert-butoxycarbonyl) glutamate were dissolved in 200 mL of tetrahydrofuran and cooled in an ice bath. Over a period of about 20 minutes, 54.6 mL (54.6 mmol) of 1 M 10 diboran/tetrahydrofuran complex in tetrahydrofuran were added dropwise with ice-cooling and under nitrogen, and the mixture was stirred on ice for 2 h and at room temperature overnight. It was cooled again to 0 *C and 58.5 mL of 1 N aqueous sodium hydroxide solution and 58.5 mL of 30% aqueous hydrogen peroxide solution were then added dropwise. After 30 minutes, the mixture was is diluted with water, the tetrahydrofuran was distilled off and the remaining aqueous solution was extracted with ethyl acetate. The organic phase was separated off, washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate was concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate 20 gradient, and the appropriate fractions were combined and concentrated. Yield: 8.5 g (52 %) MS (ESIpos): m/z = 418 [M+H]+ 1H NMR (300 MHz, CHLOROFORM-d) d ppm 1.32-1.58 (m, 27H) 1.60-1.70 (m, 25 2H) 1.73-1.94 (m, 4H) 2.05-2.12 (m, 1H), 2.33-2.40 (m, 1H) 3.58-3.68 (m, 2H) 4.15-4.22 (m, 1H) 4.95-5.03 (d, 1H) c) Di-tert-butyl (2S, 4S)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxv)propVl-qlutamate WO 2011/060887 PCT/EP2010/006766 -48 CH 0 O CH
H
3 C NO 3 IHN y0 C Or 0 CH 3 O=S=0 H3C CH 3
CH
3 418 mg (1 mmol) of di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3 hydroxypropyl)-glutamate were dissolved in 20 mL of dichloromethane and cooled in an ice-bath. After addition of 0.83 mL (6 mmol) of triethylamine and 5 229 mg (2 mmol) of methanesulphonyl chloride, the mixture was stirred on ice for 2 h and then concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the appropriate fractions were combined and concentrated. Yield: 350 mg (70.6%) 10 MS (ESIpos): m/z = 496 [M+H]+ 1H-NMR (300MHz, CHLOROFORM-d): Shift [ppm]= 1.44-147 (m, 27H), 1.61 1.96 (m, 6H), 2.32-2.41 (q, 1H), 3.02 (s, 3H), 4.11-4.18 (m, 2H), 4.88-4.91 (d, 1 H). 15 Example 3 Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-[3 (tosyloxy)propy]-gI utamate
CH
3 O 0 CH 4 3 >J 2 0 .kCH 3
H
3 C 0 CH HN 0 0
CH
3 O=s=O H3C CH 3
CH
3 418 mg (1 mmol) of di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3 20 hydroxypropyl)-glutamate were dissolved in 20 mL of dichloromethane and cooled in an ice-bath. After addition of 0.61 g (6 mmol) of triethylamine and 0.38 g (2 mmol) p-toluenesulphonyl chloride, the mixture was stirred on ice for 2 h, overnight at room temperature and then concentrated. The crude product WO 2011/060887 PCT/EP2010/006766 - 49 obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the appropriate fractions were combined and concentrated. Yield: 0.37 g (64.7 %) 5 MS (ESipos): m/z = 572 [M+H]+ 1H NMR (300 MHz, CHLOROFORM-d) d ppm 1.37-1.93 (m, 33H) 2.18-2.35 (m, 4H) 4.01-4.16 (m, 3H) 4.84 (d, 1H) 7.35 (d, 2H) 7.78 (d, 2H) 10 Example 4 Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4 nitrophenyl)-sulfonyl]oxy}propyl)-glutamate CH O 0 CH H C Ok3 3 H 3 C 0 0 CH 3 HN 0 0 0 O CH 3 O=s=O H3C CH 3
NO
2 5.22 g (12,5 mmol) of di-tert-butyl (2S 4S)-N-(tert-butoxycarbonyl)-4-(3 hydroxypropyl)-glutamate were dissolved in 125 mL of dichloromethane and 15 cooled in an ice-bath. After addition of 7.59 g (75 mmol) of triethylamine and 5.54 g (25 mmol) nitrophenylsulfonyl chloride, the mixture was stirred on ice for 2 h and then concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the appropriate fractions were combined and concentrated. 20 Yield: 4.7 g (62.4 %) MS (ESIpos): m/z = 603 [M+H]+ 1H NMR (300 MHz, CHLOROFORM-d) d ppm 1.42-1.45 (m, 27H) 1.57-1.87 (m, 6H) 2.29 (m, 1H) 4.01 (m, 1H) 4.13-4.16 (m, 2H) 4.86 (d, 1H) 8.12 (d, 2H) 8.42 25 (d, 2H) Example 5 One-pot synthesis of (2S,4S)-4-(3-["F]Fluoropropyl)-glutamic acid starting from Dimethyl (2S,4S)-N-(tert-butoxycarbonyl)-4- WO 2011/060887 PCT/EP2010/006766 - 50 [3-(mesyloxy)propy]- glutamate using a "Eckert&Ziegler modular lab" synthesizer 0 0 0 0 0 0 HaC'O OCH., .H3C'O) OCH HO OH HN O HN 0 NH 2 0 CH 3 13F O CH8 18F O=S=O CH 3 HC CH
CH
3 5 The syntheses were performed on a remote controlled synthesizer, "Eckert&Ziegler modular lab" (Figure 1). a) Purification using Hilic SPE 10 [F-18]fluoride (29.6 GBq) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1 mL kryptofix/potassium carbonate solution (acetonitrile/water) into the reaction vessel. The mixture was dried (120 *C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg mesylate precursor in 1 mL acetonitrile were added to the is dried residue and the resulting solution was stirred at 110 0 C (displayed reactor temperature) for 10 min. The solvent was evaporated (110 *C, nitrogen stream) and 1 mL 4N HCI was added. The mixture was heated at 150 0 C for 5 min. After cooling to 60 *C, the solution was diluted with acetonitrile (80 mL) and passed through a Hilic cartridge (ZIC 20 Hilic SPE, 3 ml, 1 g, SeQuant). The cartridge was dried by nitrogen steam, washed with ethanol (3 mL) and dried with stream of nitrogen. (2S,4S)-4-{3-[F 18]fluoropropyl}-glutamic acid was eluted with 10 mL buffer (70 mg Na 2
HPO
4 2H 2 0, 60 mg NaCI in 10 mL water) into the product vial. Radiochemical yield: 3.6 GBq (19 % decay corrected (d.c.)) 25 Overall process time: 61 min Radiochemical purity: 90 % (determined by TLC, Figure 2) b) Purification using MCX SPE [F-18]fluoride (24.6 GBq) was trapped on a QMA cartridge (Waters, SepPak 30 light). The activity was eluted with 1 mL kryptofix/potassium carbonate solution WO 2011/060887 PCT/EP2010/006766 -51 (acetonitrile/water) into the reaction vessel. The mixture was dried (120 "C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg mesylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 110 0C for 10 min. The 5 solvent was evaporated (110 *C, nitrogen stream) and 1 mL 4N HCl was added. The mixture was heated at 150 "C for 5 min. After cooling to 60 *C, the solution was diluted with water (3 mL) and passed through a MCX cartridge (Oasis MCX 20cc (1g), Waters). The cartridge was washed with 1N HCI (4 mL) and ethanol (5 mL) and (2S,4S)-4-{3-[F-18]fluoropropyl}-glutamic acid was eluted with 5 mL 1o buffer (sodium bicarbonate) into the product vial. Radiochemical yield: 4.6 GBq (28 % d.c.) Overall process time: 64 min Radiochemical purity: 95 % (determined by TLC, Figure 3) 15 Example 6 One-pot synthesis of (2S,4S)-4-(3-[ 1 "F]Fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4S)-N-(tert butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate using a "Eckert&Ziegler modular lab" synthesizer H a O CH H O 0 CH O O O-O-C---"-C--O-C--- - H OH - 0 HN 0 HN o NH 2 0 CH 1F 0 CH 3 1 8 F Oy HaCCa HCC 3== CH 3
CH
3 20 CH, The synthesis were performed on a remote controlled synthesizer, "Eckert&Ziegler modular lab" (Figure 1). [F-18]fluoride (32.2 GBq) was trapped on a QMA cartridge (Waters, SepPak 25 light). The activity was eluted with 1 mL kryptofix/potassium carbonate solution (acetonitrile/water) into the reaction vessel. The mixture was dried (120 *C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg mesylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 110 *C for 10 min. The 30 solvent was evaporated (110 *C, nitrogen stream) and 1 mL 4N HCI was added.
WO 2011/060887 PCT/EP2010/006766 -52 The mixture was heated at 120 "C for 10 min. After cooling to 60 *C, the solution was diluted with water (3 mL) and passed through a MCX cartridge (Oasis MCX 20cc (1g), Waters). The cartridge was washed with 0.1N HCI (4 mL) and ethanol (5 mL) and (2S,4S)-4-{3-[F-18]fluoropropyl}-glutamic acid was 5 eluted with 5 mL buffer (sodium bicarbonate) into the product vial. Radiochemical yield: 2.3 GBq (11 % d.c.) Overall process time: 60 min Radiochemical purity: 90 % (determined by TLC, Figure 4) io Example 7 One-pot synthesis of (2S,4S)-4-(3-[1F]Fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4S)-N-(tert butoxyca rbonyl)-4-[3-(tosyloxy)propy]-g lutamate using a "Eckert&Ziegler modular lab" synthesizer
H
3 C~ H 3 C~ 2 K L H--------- O--O-H--H-O--OOH O O H 3 C O YO H O OC a HO OH HN 0 HN 0 NH 2 0 CH 18 F 0 Ci-I 18F O CHC CHCH 15 HC The synthesis were performed on a remote controlled synthesizer, "Eckert&Ziegler modular lab" (Figure 1). [F-18]fluoride (22.9 GBq) was trapped on a QMA cartridge (Waters, SepPak 20 light). The activity was eluted with 1 mL kryptofix/potassium carbonate solution (acetonitrile/water) into the reaction vessel. The mixture was dried (120 0 C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg tosylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 100 0C for 10 min. The solvent 25 was evaporated (110 *C, nitrogen stream) and 1 mL 2N HCl was added. The mixture was heated at 120 0C for 10 min. After cooling to 60 *C, the solution was diluted with water (3 mL) and passed through a MCX cartridge (Oasis MCX 20cc (1g), Waters). The cartridge was washed with 0.1N HCI (4 mL) and ethanol (5 mL) and (2S,4S)-4-{3-[F-18]fluoropropyl}-glutamic acid was 30 eluted with 3 mL buffer (sodium bicarbonate) into the product vial.
WO 2011/060887 PCT/EP2010/006766 - 53 Radiochemical yield: 3.6 GBq (26 % d.c.) Overall process time: 57 min Radiochemical purity: 99 % (determined by TLC, Figure 5) 5 Example 8 One-pot synthesis of (2S,4S)-4-(3-["F]Fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4S)-N-(tert butoxycarbonyl)-4-(3-{[(4-nitrophenyl)sulfonyl]oxy}propyl) glutamate using a "Eckert&Ziegler modular lab" synthesizer (Figure 1) 10 CH 0 0H HC H3 0 0 H0 0 H>l,. VCH 2
U
0 1 3L 1Z~ )~Q-H 30 O C C ''C Ho OH HN 0 HN 0 NH 2 0 CH3 0F O CH 3 18F 00 H cCH H3CH3
NO
2 The syntheses were performed on a remote controlled synthesizer, "Eckert&Ziegler modular lab" (Figure 1). 15 a) Fluorination using [F-18]fluoride/kryptofix/potassium carbonate [F-1 8]fluoride (see Table 1 for details) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1.5 mL kryptofix/potassium carbonate 20 solution (acetonitrile/water) into the reaction vessel. The mixture was dried (120 *C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg nosylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred (for reaction time and temperature see Table 1). 2N HCI (2 mL) was added without previous 25 evaporation and the mixture was heated at 100 0C for 5 min. After cooling to 60 "C, the solution was diluted with water (50 mL) and passed through a HR-P (Chromafix HR-P, Macherey-Nagel) and a MCX cartridge (Oasis MCX 20cc (1g), Waters). The MCX cartridge was washed with saline (20 mL) and (2S,4S) 4-{3-[F-18]fluoropropyl}-glutamic acid was eluted with 10 mL buffer (70 mg WO 2011/060887 PCT/EP2010/006766 - 54 Na 2
HPO
4 2H 2 0, 60 mg NaCI in 10 mL water) into the product vial. Results are summarized in Table 1. Table 1 Results conversion of nosylate precursor reaction reaction radiochem. overall radiochem. Diastereo entry temperature time yield process. purity (TLC) meric purity* tempratue tme yeldtime 1 80 0C 10 min 1.0 GBq 46 min 94% 92% (73 % d.c.) 2 80 C 5 min 1.2 GBq 44 min 97% 95% (61 % d.c.) 3 80 *C 1 min 2.0 G 41 min 97% 97% 8000 1 mm (63 %d.c.) 4 60 *C 5 min 35 GBq 44 min 98 % 97% 6000 5mm (56 %d.c.) 5 60 *C 1 min 6.3 GBq 41 min 98% 98% 6000 1 mm ~(67 % d.c.) __ _ _ _ __ ____ _____ 5 * determined by HPLC. Radiochemical purity and diastereomeric ratio was determined by pre-column derivatization HPLC (Figure 8). b) Fluorination using [F-1 8]fluoride/tetrabutyl ammonium bicarbonate io [F-18]Fluoride solution was passed through on a column packed with DOWEX 1x8-200 (40 mg) which was subsequently flushed with inert gas. [F-1 8]Fluoride was eluted from the column with an aqueous solution of tetrabutylammonium bicarbonate (n-Bu 4
NHCO
3 ) in water/acetonitrile into the reactor vessel. The mixture was dried by heating under a stream of inert gas. The drying procedure 15 was repeated after addition of 1 ml acetonitrile. 5 mg noslyate precursor in 1 mL acetonitrile were transferred into the reactor vessel containing the dried tetrabutylammonium [F-18]Fluoride. The mixture was heated at 80 *C for 10 min. After cooling, 2N HCI (1 mL) was added and the mixture was heated at 100 0 C. Subsequently, 2N NaOH (1.35 mL) was added 20 followed by heating at 80*C. The reaction mixture was transferred into a mixing vessel (filled with 50 mL 0.1NHCI). The reactor vessel was washed with water into the mixing vessel. The water solution containing the radiolabeled product was passed through a HR-P cartridge onto two MCX plus (SepPak plus, waters) cartridges. After the MCX cartridges are washed with 20mL isotonic saline, 25 residual saline was removed with argon. Finally, the product was eluted from the WO 2011/060887 PCT/EP2010/006766 - 55 two cartridges with 20 mL isotonic buffer 140 mg Na 2
HPO
4 -2H 2 0 and 120 mg NaCl in 20 mL water) into the product vail. Radiochemical yield: 12.9 GBq (40 % d.c.) Radiochemical purity: 97 % 5 Isomeric purity: > 98 % c) Fluorination using [F-1 8]fluoride/tetrabutyl ammonium bicarbonate [F-18]Fluoride solution was passed through a QMA cartridge (QMA light, Waters) which was subsequently flushed with inert gas. [F-18]Fluoride was 1o eluted from the column with an aqueous solution of tetrabutylammonium bicarbonate (n-Bu 4
NHCO
3 ) in water/acetonitrile into the reactor vessel. The mixture was dried by heating under a stream of inert gas. The drying procedure was repeated after addition of 1 ml acetonitrile. 5 mg noslyate precursor in 1 mL acetonitrile were transferred into the reactor 15 vessel containing the dried tetrabutylammonium [F-18]Fluoride. The mixture was heated at 80 *C for 700 s. After cooling, 2N HCI (1 mL) was added and the mixture was heated at 100 0 C. Subsequently, 2N NaOH (1.35 mL) was added followed by heating at 800C. The reaction mixture was transferred into a mixing vessel (filled with 50 mL 0.1NHCI). The reactor vessel was washed with water 20 into the mixing vessel. The water solution containing the radiolabeled product was passed through a HR-P cartridge onto two MCX plus (SepPak plus, waters) cartridges. After the MCX cartridges are washed with 20mL isotonic saline, residual saline was removed with argon. Finally, the product was eluted from the two cartridges with 20 mL isotonic buffer 140 mg Na 2
HPO
4 -2H 2 0 and 120 mg 25 NaCI in 20 mL water) into the product vail. Radiochemical yield: 40±6.4% (corrected for decay) Radiochemical purity: 92.4±2.3% % Diastereomeric ratio: >98/2 Radiochemical purity and diastereomeric ratio was determined by pre-column 30 derivatization HPLC (Figure 9). Example 9 One-pot synthesis of (2S,4S)-4-(3-["F]Fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4S)-N-(tert- WO 2011/060887 PCT/EP2010/006766 -56 butoxycarbonyl)-4-(3-{[(4-nitrophenyl)sulfonyl]oxylpropyl) glutamate using a "GE tracerlab FX" synthesizer (Figure 6) CH O O CH CH O 0 H 0 0 OHO C OH CH 3 ' HO'U 4 <IOH HN 0 HN 0 NH 2 0 CH3 1 sF 0 CH 3 1 sF O=S=O HacCH H CH3
NO
2 5 [F-18]fluoride (1.6 GBq) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1.5 mL kryptofix/potassium carbonate solution (acetonitrile/water) into the reaction vessel. The mixture was dried (120 "C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml 10 acetonitrile. 5 mg nosylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 60 "C for 10 min. 2N HCI (2 mL) was added without previous evaporation and the mixture was heated at 110 *C for 5 min. After cooling to 60 *C, the solution was diluted with water (50 mL) and passed through a HR-P (Chromafix HR-P, Macherey-Nagel) and a 15 MCX cartridge (Oasis MCX 20cc (1g), Waters). The MCX cartridge was washed with saline (10 mL) and (2S,4S)-4-{3-[F-18]fluoropropyl}-glutamic acid was eluted with 10 mL buffer (70 mg Na 2
HPO
4 2H 2 0, 60 mg NaCl in 10 mL water) into the product vial. Radiochemical yield: 0.46 GBq (39 % d.c.) 20 Overall process time: 51 min Radiochemical purity: 95 % (determined by TLC) Example 10 Synthesis of (2S,4S)-4-(3-[ 8 F]Fluoropropyl)-glutamic acid 25 starting from Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3 {[(4-nitrophenyl)sulfonyl]oxy}propyl)-glutamate using a "GE tracerlab MX" synthesizer WO 2011/060887 PCT/EP2010/006766 -57 H H HOC CH O 3 0 0 H 0 0 3 CC 3 OCH 3I HC 4 2 C -a . HC OA (lO C HO'<<'OH HN 0 HN 0 NH 2 0 O CH, ' 8 F O CH, 18F 0=S=0 3 CH HC CH 3
NO
2 a) For synthesis of on the cassette type synthesizer "GE Tracerlab MX" a kit was assembled 5 A commercially available FDG cassette (GE) was adopted: - tC18 and alumina N cartridges were removed and the second and third manifold were connected with a tube, - the "green spike" (originally used for the "buffer vial" of the FDG process was 10 removed). The reagent kit for the (2S,4S)-4-(3-[ 18 F]fluoropropyl)-glutamic acid synthesis process included: - A preconditioned QMA cartridge (Waters, ABX), - A "eluent vial": potassium carbonate, kryptofix in 300 pL MeCN and 300 pL 15 water (for detailed composition see Table 2 and the description within passage "c" of the present example), - A blue capped vial, filled with 8 mL MeCN (to be placed on valve "3" of the modified FDG cassette), - Two empty 30 mL syringes, 20 - A red capped "precursor vial", filled with a solution of Di-tert-butyl (2S,4S)-N (tert-butoxycarbonyl)-4-(3-{[(4-n itrophenyl)sulfonyl]oxy}propyl)-glutamate in 1.5 ml MeCN (to be placed on valve "5" of the modified FDG cassette), - A "water bag" (filled with 100 or 250 mL water for injectable solutions), - A yellow capped "HCI vial", filled with 2 ml 2M HCI (to be placed on valve "8" 25 of the modified FDG cassette), - A 20 mL syringe filled the formulation buffer (140 mg Na 2
HPO
4 2H 2 0, 120 mg NaCI dissolved in 20 mL water for injectable solutions, to be placed on valve "9" of the modified FDG cassette, WO 2011/060887 PCT/EP2010/006766 -58 - 3 MCX plus (Waters) cartridges (to be placed between valves 12 and 13 of the modified FDG cassette), - A 500 mg Hypercarb cartridge (Thermo Fischer, to be placed between valve 11 of the modified FDG cassette and the product vial), 5 - A sterile product vial (20 mL or 30 mL), - A needle and a sterile filter, - A vent needle and a sterile vent filter. b) Radiosynthesis using Tracerlab MX, investigation of influence of temperature 10 and base/precursor ratio The synthesis of (2S,4S)-4-(3-[ F]fluoropropyl)-glutamic acid was performed using an adapted sequence program, wherein: - The "acetonitrile vial", the "precursor via" and the "HCI vial" were pressurized, 15 - [F-18] fluoride was transferred to the Tracerlab MX and loaded onto the QMA cartridge, - The activity was transferred using the solution in the "Eluent vial" into the reactor. - The mixture was dried at 95 % using nitrogen stream, vacuum and the 20 addition of acetonitrile portions, - The solution of the "precursor vial" was transferred to the reactor (resulting in 4.5±0.5 mg precursor in the reactor) and the resulting mixture was heated for 5 min (for "reaction temperature" see Table 2 and description within passage "c" of the present example, 25 - HCI from the "HCI vial" was transferred to the reactor vial using the 30 mL syringes and the mixture was heated at 120 *C for 10 min, - The crude product mixture was diluted in the left 30 mL syringe with water (from "water bag") and passed through the MCX cartridges into the waste bottle, 30 - The MCX cartridges were washed with 30 mL water (from "water bag"), - The formulation buffer solution was transferred from the 20 ml syringe into the 30 ml syringe and subsequently passed through the MCX cartridges and the Hypercarb cartridge into the product vial.
WO 2011/060887 PCT/EP2010/006766 - 59 The overall synthesis time of the process was 34-35 min. The influence of reaction temperature and composition of the "eluent vial" was investigated, the results are summarized in Table 2. No epimerization was found 5 using base/precursor ratios below 1 (entry 1-8), whereas low reaction temperatures are needed to prevent significant epimerization at base/precursor ratio greater than 1 (entry 9, 12, 15). Table 2 Results of conversion of noylate precursor Ratio of K 2 CO3 reaction Composition of / labeling radiochem. diastereo entry temperature "eluent vial" precursor purity meric purity 1 70 *C 0.5 mg K2CO3, > 95 % > 98 / 2 2 90 *C 2.5 mg kryptofix, 0.48 > 95 % > 98/ 2 _________ 300 pL MeCN, 3 120 *C 300 pL H 2 O > 95 % > 98/2 4 70 0C 0.75 mg K 2
CO
3 , > 95 % > 98 /2 3.75 mg kryptofix, 0.73 5 120 *C 300 pLMeCN, > 95 % > 98 / 2 ______ __________ 300 p L H 2 0 ______________ 6 70 *C 1.0 mg K 2
CO
3 , > 95 % > 98/2 7 90 C 5.0 mg kryptofix, 0.97 > 95 % >98 / 2 90 00 300 pL MeCN, 8 120 *C 300 pL H 2 0 > 95 % > 98 / 2 9 70 "C 1.15 mg K 2
CO
3 , > 95 % > 98 / 2 10 90 0C 5.12 mg kryptofix, 1.11 > 95 % 95/5 300 pL MeCN, 11 120 *C 300 pL H 2 0 > 95 % 60/40 12 70 0C 1.3 mg K 2
CO
3 , > 95 % ~98/2 13 90 *C 6.5 mg kryptofix, 1.26 > 95 % 92 / 8 300 pL MeCN, 14 120 *C 300 pL H 2 0 > 95 % 60/40 15 70 0C 1.5 mg K2CO3, > 95 % -95/5 16 90 0C 7.5 mg kryptofix, 1.45 > 95 % 82/18 ____ _______ 300 pLMeCN, 17 120 0C 300 pL H 2 O > 95 % 50/50 18 15 2.0 mg K 2
CO
3 , > 95 % =95/5 19 9000 * 10.0 mg kryptofix, 1.94 >95% 78/22 19___ 90____*C _ 300 pL MeCN, 20 120 *C 300 pL H 2 O > 95 % 50/50 WO 2011/060887 PCT/EP2010/006766 - 60 a) determined by TLC and HPLC; b) given as diastereomeric ratio, determined by HPLC (for examples see Figures 10, 11) c) Routine synthesis of (2S,4S)-4-(3-[ 18 F]fluoropropyl)-glutamic acid on 5 Tracerlab MX A reagent kit as described within passage "a" of the present example was used. The "Eluent vial" was filled with a solution of 1.0 mg K 2
CO
3 , 5.0 mg kryptofix in 300 pL MeCN and 300 pL H 2 0. 1.1 - 86 GBq [F-1 8]fluoride (n > 20) were transferred the Tracerlab MX. The activity was trapped on the QMA cartridge 10 (QMA light, Waters) and eluted using the mixture in the "Eluent vial" into the reactor vial. The mixture was dried at 95 0 C using nitrogen stream and vacuum. Drying was repeated after addition of portions of acetonitrile. The solution of the "Precursor vial" was transferred to the reaction vial to reach a amount of 4.5±0.5 mg Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4 15 nitrophenyl)sulfonyl]oxy}propyl)-glutamate in the reactor. The mixture was heated at 70 *C for 5 min. The acid from the "HCI vial" was transferred via the 30 mL syringes into the reaction vial and the mixture was heated at 120 *C for 5 min with open exhaust and 5 min with closed exhaust. In the left 30 mL syringe, the crude product mixture was diluted with water (20 mL) and passed through 3 20 MCX cartridges (MCX plus, Waters). The cartridges were washed with 30 mL water. The formulation buffer was transferred from the 20 mL syringe at valve 9 into the right 30 mL syringe and passed through the MCX cartridges and the Hypercarb cartridge (500mg, Thermo Scientific) into the product vial. 0.5 - 41 GBq (44 - 56% not corrected for decay) (2S,4S)-4-(3-[ 1 5 F]fluoropropyl) 25 glutamic acid were obtained in 34-35 min synthesis time. The radiochemical purity was determined to be greater than 98% using Radio-TLC; HPLC and Derivatization-HPLC. 30 Example 11 One-pot synthesis of (2S,4S)-4-(3-[ 18 F]fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4S)-N-(tert butoxycarbonyl)-4-(3-{[(4-nitrophenyl)sulfonyl]oxy}propyl) glutamate using a "GE tracerlab FX" synthesizer (Figure 7) WO 2011/060887 PCT/EP2010/006766 -61 [F-18]fluoride (3.97 GBq) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1.5 mL kryptofix/potassium carbonate solution (5 mg kryptofix,1mg potassium carbonate in 1.25 mL acetonitrile and 0.25 mL water) into the reaction vessel. The mixture was dried (120 *C, nitrogen stream, 5 vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg nosylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 70 0C for 5 min. 2M HCI (1 mL) was added without previous evaporation and the mixture was heated at 110 *C for 10 min. After cooling to 60 *C, the solution was diluted with water (10 mL) and passed 10 through 3 MCX cartridges (MCX plus, Waters). The MCX cartridges were washed with water (2 x 10 mL) and 15 mL formulation buffer (105 mg Na 2
HPO
4 2H 2 0, 90 mg NaCI in 15 mL water) were passed trough the MCX cartridges and a Hypercarb cartridge (500 mg, Thermo Scientific) into the product vial. 1.8 GBq (46 % not corrected for decay) (2S,4S)-4-{3-[ F]fluoropropyl}-glutamic 15 were obtained in 41 min synthesis time. The radiochemical purity and diastereomeric excess was determined to be greater than 98% using Radio TLC; HPLC and Derivatization-HPLC. 20 Example 12 Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4 nitrophenyl)-sulfonyl]oxy)propyl)-glutamate HcCH O 0 CH 3
H
3 c >l, 0 2 ,,-H HN 0 CH3 0 ~0 'CH3 o=s=o H3CH 3
NO
2 a) Di-tert-butyl (4S)-2-[3-(benzyloxy)-1-hydroxypropyll-4-[(tert-butoxvcarbonvl) aminopentanedioate WO 2011/060887 PCT/EP2010/006766 -62 HCCH 3o 0 CH 3
H
3 C 2 CH, HO HN o
CH
3 0
CH
3 & H~3C
H
3 5.39 g (15 mmol) of di-tert-butyl Boc glutamate (Journal of Peptide Research (2001), 58, 338) were dissolved in 45 mL of tetrahydrofuran (THF) and cooled to -70 0 C. 33 mL (33 mmol) of a 1M solution of lithium bis(trimethylsilyl)amide in 5 THF were added dropwise over a period of 45 min at this temperature and the mixture was stirred at -70 *C for another 2 hours. A solution of 2.96 g (18 mmol) of 3-(benzyloxy)propanal (J Org Chem, 47(27), 5400 (1982)) in 5 mL of THF was then added dropwise, and after 2 h at this temperature, the cooling bath was removed and 75 mL of 2N aqueous hydrochloric acid and 200 mL of io dichloromethane were added. The organic phase was separated off, washed with water until neutral, dried over sodium sulphate and filtered, and the filtrate was concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient, and the appropriate fractions were combined and concentrated. 15 Yield: 1.3 g (16.6%) MS (ESIpos): m/z = 524 [M+H]* 1 H NMR (600 MHz, CHLOROFORM-d) 6 ppm 1.41-1.47 (m, 27H) 1.70-2.20 (m, 4H) 2.40-2.53 (m, 1H) 3.11-3.38 (m, 1H), 3.59-3.78 (m, 2H) 3.91-4.01 (m, 1H) 20 4.13-4.20 (m, 1H), 4.52 (d, 2H) 4.93-5.09 (m, 1H), 7.28-7.37 (m, 5H) b) Di-tert-butyl (4S)-2-{3-(benzyloxy)-1 -[(methylsulfonyl)oxylpropyll-4-[(tert butoxycarbonVl)aminolpentanedioate CH 0 O CH
H
3 C> j2 4 O JCHS O HN 0 CH H3C Oo CH 3
H
3 C
CH
WO 2011/060887 PCT/EP2010/006766 - 63 4.19 g (8 mmol) of di-tert-butyl (4S)-2-[3-(benzyloxy)-1-hydroxypropyl]-4-[(tert butoxycarbonyl)amino]pentanedioate (10a) were dissolved in 120 mL of dichloromethane and cooled to 00C in an ice bath. 4.05 g (40 mmol) of triethyl amine and 1.83 g (16 mmol) of methanesulfonyl chloride were added and the 5 mixture was stirred for 2 hours at this temperature and overnight at room temperature. The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica gel using a dichloromethane / ethyl acetate gradient, and the appropriate fractions were combined and concentrated. Yield: 3.3 g (68.6%) 10 MS (ESIpos): m/z = 602 [M+H]I 'H NMR (600 MHz, CHLOROFORM-d) 6 ppm 1.42-1.47 (m, 27H) 1.64-2.09 (m, 4H) 2.80-2.83 (m, 1H) 2.99 (s, 3H), 3.57-3.61 (m, 2H), 4.46-4.56 (m, 2H) 4.91 5.10 (m, 1H), 5.12-5.15 (m, 1H), 5.30 (m, 1H), 7.29-7.35 (m, 5H) 15 c) Di-tert-butyl (2S) 4-[3-(benzvloxv)propylidenel-N-(tert-butoxvcarbonyl) qlutamate CH O 0 CH
H
3 4 2 O 3 C 0 HN 0 CH 3 0 Oy CH 3
H
3 C CH3 6.02 g (10 mmol) of di-tert-butyl (4S)-2-{3-(benzyloxy)-1 -[(methyl 20 sulfonyl)oxy]propyl}-4-[(tert-butoxycarbonyi)aminopentanedioate (10b) were dissolved in 75 mL of dichloromethane, 3.35 mL (24 mmol) of triethylamine were added and irradiated in a microwave oven at 120*C for 2h. The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica gel using a dichloromethane/ethyl acetate gradient and the appropriate fractions 25 were combined and concentrated. Yield: 3.3 g (65.3%) MS (ESipos): m/z = 506 [M+H]) WO 2011/060887 PCT/EP2010/006766 - 64 'H NMR (600 MHz, CHLOROFORM-d) 6 ppm 1.38-1.51 (m, 27H), 1.73-2.02 (m, 3H) 2.37-2.90 (m, 1H), 3.20-3.40 (m, 1H), 3.48-3.61 (m, 2H), 4.10-4.44 (m, 2H) 4.48 (m, 2H), 7.33-7.36 (m, 5H) 5 d) Di-tert-butyl (2S,4R)-4-f3-(benzyloxy)propyll-N-(tert-butoxycarbonvl) glutamate
HCCH
3 O 0 CH 3 4 2 OCH, H 3 C > 0 2 ,1 HN o OH 3 O 0 CH 3
H
3 C
CH
3 250 mg (0.5 mmol) of di-tert-butyl (2S) 4-[3-(benzyloxy)propylidene]-N-(tert butoxycarbonyl)-glutamate (10c) were dissolved in 10 mL of methanol and 40 10 microL (0.5 mmol) of pyridine. After addition of 50 mg of palladium on charcoal (10%) under nitrogen the mixture was hydrogenated overnight at room temperature. The catalyst was then filtered off and the filtrate was concentrated in vacuo. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the fractions containing the 15 diastereomeric mixture of (4R) and (4S) isomers of the title compound were combined and concentrated. This mixture was chromatographed on silica gel using a dichloromethane / ethyl acetate gradient and the appropriate fractions (Rf value (dichloromethane/ethyl acetate 19:1) = 0.40) were combined and concentrated. 20 Yield: 70 mg (27.5%) MS (ESIpos): m/z = 508 [M+H]* 1 H NMR (600 MHz, CHLOROFORM-d) 5 ppm 1.42-1.48 (m, 27H) 1.58-1.85 (m, 3H) 2.09-2.17 (m, 1H), 2.30-2.39 (m, 1H), 3.45 (m, 2H), 4.18-4.24 (m, 1H) 4.49 25 (s, 2H), 4.95-5.01 (m, 1H), 7.27-7.37 (m, 5H) e) Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonvlloxvlpropvl)-glutamate WO 2011/060887 PCT/EP2010/006766 -65 CH O 0 CH 3 H3C 4 2 O -CH, HN o CH3 o 0 150 mg (0.295 mmol) of di-tert-butyl (2S,4R)-4-[3-(benzyloxy)propyI]-N-(tert butoxycarbonyl)-glutamate (10d) were dissolved in 10 mL of methanol. 0.1 g of palladium on charcoal (15%) was added under nitrogen and the heterogeneous 5 mixture was hydrogenated at room temperature overnight. The catalyst was then filtered off and the filtrate was concentrated in vacuo. Di-tert-butyl (2S,4R) N-(tert-butoxycarbonyl)-4-(3-hyd roxypropyl)-glutamate was identified by mass spectrometry (m/z = 418 [M+H]*) and without further purification, the residue (120 mg) was dissolved in 7.5 mL of dichloromethane and cooled in an ice-bath. 10 After addition of 0.17 g (168 mmol) of triethylamine and 124 mg (0.56 mmol) nitrophenylsulfonyl chloride, the mixture was stirred on ice for 4 h, overnight at room temperature and then concentrated. The crude product obtained in this manner was chromatographed on silica gel using a hexane/ethyl acetate gradient and the appropriate fractions were combined and concentrated. 15 Yield: 105 mg (62.2 %) MS (ESIpos): m/z = 603 [M+H]* 'H NMR (600 MHz, CHLOROFORM-d) 6 ppm 1.43-1.46 (m, 27H), 1.61-1.73 (m, 6H), 2.06-2.10 (m, 1H), 2.32-2.34 (m, 1H), 4.11-4.15 (m, 3H), 4.95 (m, 1H), 20 8.10-8.12 (d, 2H), 8.40-8.43 (d, 2H) Example 13 One-pot synthesis of (2S,4R)-4-(3-["F]fluoropropyl)-glutamic acid starting from Di-tert-butyl (2S,4R)-N-(tert 25 butoxycarbonyl)-4-(3-{[(4-nitrophnyl)sulfonyl]oxy}propyl) glutamate using a "GE tracerlab FX" synthesizer (Figure 6) WO 2011/060887 PCT/EP2010/006766 -66 H3C H, 0 0 HH 3 CH, OH0 0 9 3 0 0 H 4 2 O H4 2 OH 2 H O C 00 00 OH HC HO OH 3 0 C~~H 3 30 CH H Y HN 0 Y HN 0 ' NH 2 H CH 3 isF O CH, 1SF OO CH, H 3 C CH,
NO
2 [F-18]fluoride (9.1 GBq) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1.5 mL kryptofix/potassium carbonate solution 5 (5 mg kryptofix, 1mg potassium carbonate in 1.25 mL acetonitrile and 0.25 mL water) into the reaction vessel. The mixture was dried (120 C, nitrogen stream, vacuum). Drying was repeated after addition of 1 ml acetonitrile. 5 mg nosylate precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 60 *C for 1 min. 2N HCI (2 mL) was added without io previous evaporation and the mixture was heated at 110 0C for 5 min. After cooling to 60 *C, the solution was diluted with water (50 mL) and passed through a HR-P (Chromafix HR-P, Macherey-Nagel) and two MCX plus cartridges (Waters). The MCX cartridge was washed with saline (10 mL) and (2S,4R)-4-{3-[F-18]fluoropropyl}-glutamic acid was eluted with 10 mL 15 formulation buffer (70 mg Na 2
HPO
4 2H 2 0, 60 mg NaCl in 10 mL water) into the product vial. Radiochemical yield: 4.05 GBq (63 % d.c.) Overall process time: 51 min Radiochemical purity: > 98 % (determined by TLC) 20 > 98 % (determined by HPLC) Diastereomeric ratio: > 98/2 (determined by HPLC) Example 14 One-pot synthesis of (2S,4R)-4-(3-[ 1F]fluorohexyl)-glutamic acid starting from Di-methyl (2S,4R)-N-(tert-butoxycarbonyl)-4 25 (6-iodohexyl)-glutamate WO 2011/060887 PCT/EP2010/006766 -67 0 0 0 0 0 0 H3C'O OC4 2 H C'OA 2 O, Ha OO HN O HN 0 NH 2 0 CH 3 O CH3
H
3 C CH HC CH 3 F 'F [F-18]fluoride (1.5 GBq) was trapped on a QMA cartridge (Waters, SepPak light). The activity was eluted with 1.5 mL kryptofix/potassium carbonate solution (5 mg kryptofix,1mg potassium carbonate in 1.25 mL acetonitrile and 0.25 mL 5 water) into the reaction vial. The mixture was dried (120 0C, nitrogen stream). Drying was repeated after addition of 1 ml acetonitrile. 5 mg iodo precursor in 1 mL acetonitrile were added to the dried residue and the resulting solution was stirred at 110 0C for 10 min. The mixture dried under gentle nitrogen stream at 110 *C. After cooling to 60 'C, 4M HCI (2mL) was added and the mixture was 10 stirred at 150 *C for 10 min. After cooling to 60 *C, the solution was diluted with water (50 mL) and passed through a OASIS HLB cartridge (HLB plus, Waters). The cartridge was washed with 2M HCI (10 mL) and water (10 mL). 422 MBq (41% d.d.) (2S,4S)-4-{6-[F-18]fluorohexyl}-glutamic acid were eluted with 5 mL formulation buffer into the product vial. 15 The radiochemical purity was determined by Derivatization-HPLC to be 93% (Figure 12).

Claims (14)

1. A method for producing compound of Formula I 0 0 HO OH 18FX NH 2 5 comprising the steps of: Step 1: Synthesizing radiolabeled compound of Formula IlIl by reacting compound of Formula |1 with a F-18 fluorinating agent, 0 0 0 0 RLO O-R 2 X NR 3 R 4 RLO O-R 2 LG 1 F-X NR 3 R 4 I| III io Step 2: Cleavage of the protecting groups of compound of Formula IlIl to obtain compound of Formula 1, Step 3: Purification and formulation of compound of Formula I wherein: X is selected from the group comprising is a) bond, b) branched or non-branched (C2-C1O)alkyl, c) branched or non-branched (C2-C1O)alkoxy, d) branched or non-branched (C3-C1O)alkenyl, e) branched or non-branched (C3-C1O)alkynyl, 20 f) [(CH 2 )n-Olm-(CH 2 )o, and g) 0-[(CH 2 )n-Om-(CH 2 )o; n = 2-6, preferably n = 2 or 3; m = 1-3, preferably m = 1 or 2; o = 2-6, preferably o = 2 or 3; 25 R1 and R2 are carboxyl-protecting groups and wherein carboxyl-protecting group is independently from each other selected from WO 2011/060887 PCT/EP2010/006766 69 a) branched or non-branched (C-Ce)alkyl, b) benzyl, and c) allyl; R 3 and R 4 are independently from each other selected from the group 5 comprising: a) hydrogen, b) an amine-protecting group or c) the group NR 3 R 4 is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl (phthalimido) or an azido group; and io encompassing single isomers, tautomers, diastereomers, enantiomers, mixtures thereof and suitable salts thereof.
2. The method according to claim 1 wherein Step 3 comprises a solid-phase extraction, preferably a cation exchange solid phase. 15
3. The method according to claims 1 and/or 2 wherein the [8F] fluorination reaction described in Step 1 is carried out at 0 *C - 160 "C.
4. The method according to any claims 1 to 3 wherein the [ 18 F] fluorination 20 agent used in Step 1 is generated from a base and [ 18 F]fluoride and the ratio of the base and compound of Formula |1 is greater than zero (>0) and equal or below 1 (51).
5. The method according to claims 1 to 4 wherein compound of Formula I has 25 an isomeric purity of greater than 90 % .
6. The method according to claims 1 to 5 wherein the method is automated and / or remote controlled. 30
7. The method according to claims 1 to 6 wherein compound of Formula I is (2S,4R)-4-(3-[ 18 F]Fluoropropyl)-glutamic acid WO 2011/060887 PCT/EP2010/006766 70 O 0 HO OH NH 2 is F
8. The method according to claims 1 to 6 wherein compound of Formula I is (2S,4R)-4-(3-[ 1 F]Fluoropropyl)-glutamic acid O 0 4 2 HO OH NH 2 5 18 F
9. The method according to claims 1 to 6 wherein compound of Formula I is selected from the group comprising: Di-tert-butyl (2 S,4S)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate CH 0 0 CH H 3C Ok O 3 HN 0 3 O 0 CH 3 0=$=0 H3 CH 3 10 CH O Di-tert-butyl (2 S,4S)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propy]-gIutamate H 3 C H 0 OCH -HN 0 o 0 H O- H CH H3 0OH O=S=O H3C CH3 CH 3 15 Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) su lfonyl]oxy}propyl)-g luta mate WO 2011/060887 PCT/EP2O1O/006766 71 CH0 0 0 CH H 3 3 0S0OH N N T 0 Di-tert-butyl (2 S, 4R)-N-(tert-b utoxyca rbo nyl)-4-[3-(m esyloxy]) propy]-glIuta mate CH 3 0 0 CH 3 YHN 0 C 0 CH3 OH 3 Di-tert-butyl (2 S,4R)-N-(tet-butoxycarbo nyl)-4-[3-(tosyloxy) propyl-g luta mate H 3OcCH 3 0 4 2 H 0H H 3 C > 0 0 OH 3 HN y0 0 OH 3 O H 3 ,or Di-tert-butyl(2 S,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonyl]oxy}propyl)-g lutamate WO 2011/060887 PCT/EP2010/006766 72 H CH3 0 O CH3C H 3 C a 4 2 C H 3 C 0 0 CH 3 HN 0 o O CH: I )<CH3 0=S=0 CH 3 NO 2
10. A compound of Formula Ila or lib 0 0 0 0 R VR 2" R O. R 2 NR R 4 X NR 3 R 4 Ila or Ilob 5 wherein: X" is selected from the group comprising a) branched or non-branched (C2-C10)alkyl, b) branched or non-branched (C2-C10)alkoxy, 10 c) branched or non-branched (C3-C10) alkenyl with the proviso that LG is not attached to a sp2 hybridized carbon atom, d) branched or non-branched (C3-C10) alkynyl, with the proviso that LG is not attached to a sp hybridized carbon atom, e) [(CH 2 )n--O]m--(CH 2 )o', and 15 f) 0-[(CH 2 )n0-]m"-(CH 2 )o" wherein n"= 2-6, preferably n" = 2 or 3, m"= 1-3, preferably m" = 1 or 2, o"= 2-6, preferably o" = 2 or 3, 20 R' and R2" are carboxyl-protecting groups and wherein carboxyl-protecting group is independently from each other selected from a) branched or non-branched (C 1 -C 6 )alkyl, WO 2011/060887 PCT/EP2010/006766 73 b) benzyl, and c) allyl; R 3 " and R4" are independently from each other selected from the group comprising: 5 a) hydrogen, b) an amine-protecting group or the group NR 3 R 4 " is a 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl (phthalimido) or an azido group and encompassing single isomers, tautomers, and suitable salts thereof io preferably compound of Formula Ila is Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-g glutamate CH 0 0 CH 3 H 3 >J 3 -_ 2 l H HC 0 0 OCH 3 HN O 03 0 OH 3 OHH 3 O= =O CHCH CH3 Di-tert-butyl (2 S,4S)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propyl-g glutamate CH 0 0 OH 3 4 2 CHs HGC 0 0 OH 3 HN 0 O CH3 O=s=O CH 3 CH 3 15 Di-tert-butyl (2S,4S)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) sulfonyl]oxy}propyl)-glutamate WO 2011/060887 PCT/EP2010/006766 74 C H 3 0 0 CH 3 O) O CH 3 HN 0 0 0 COH3 0=S0 CH 3 NO 2 Di-methyl (2S,4R)-N-(tert-butoxycarbonyl)-4-(6-iodohexyl)-g glutamate O 0 H 3C'O O' CH 3 0*- 0' HN 0 O CH 3 H 3 C CH 3 or preferably, compound of Formula lIb is: 5 Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-[3-(mesyloxy])propy]-glutamate H3CH 3 4 CH H 3 C 0 O CH 3 HN 0 O CH 3 O CH O=s3=O CH, 3 CH 3 Di-tert-butyl (2S,4R)-N-(tert-butoxycarbonyl)-4-[3-(tosyloxy)propy]-glutam ate CH3 0 0 CH 3 H 3 O 4 2 ACH3 H3C O O CH3 HN 0 0 CH 3 0 0CH 3 OS= CH 3 CH3 ,or WO 2011/060887 PCT/EP2010/006766 75 Di-tert-butyl(2S,4R)-N-(tert-butoxycarbonyl)-4-(3-{[(4-nitrophenyl) su Ifonyl]oxy}propyl)-glutamate H 3 C>H 0 0 CH 3 H 3 C 4 2 CH3 H3C O O CH 3 HN 0 OCH o YCH 3 0SO CH 3 NO 2 5
11. A compound of Formula lb O 0 HO OH 1 ' NH 2 lb wherein: X' is selected from the group comprising a) branched or non-branched (C2-C10)alkyl, 10 b) branched or non-branched (C2-C10)alkoxy, c) branched or non-branched (C3-C10) alkenyl with the proviso that 18F is not attached to a sp2 hybridized carbon atom, d) ,branched or non-branched (C3-C10) alkynyl, with the proviso that 18F is not attached to a sp hybridized carbon atom, 15 e) [(CH 2 )n'-0]m-(CH 2 )o., and f) 0-[(CH 2 )n'-0]m-(CH 2 )o'; n' = 2-6, preferably n' = 2 or 3; m'= 1-3, preferably m' = 1 or 2; o' =2-6, preferably o' = 2 or 3; 20 and encompassing single isomers, tautomers, diastereomers, enantiomers, mixtures thereof and suitable salts thereof , preferably (2S,4R)-4-(3-[ 18 F]Fluoropropyl)-glutamic acid WO 2011/060887 PCT/EP2010/006766 76 0 0 4 2 HO OH NH 2
12. A method for obtaining a formulation comprising compound of Formula I, Formula la, or Formula Ib, or mixture thereof comprises the step of adding one 5 or more physiologically acceptable vehicle or carrier, adjuvants or preservatives to a solution of compound of Formula I, Formula Ila, or Formula Ib, or mixture thereof.
13. Use of a device for carrying out the method according to claims 1 to 9 for 1o producing compound of Formula 1.
14.A Kit for producing of compound of Formula I according to claims 1 or 11. comprising - a predefined quantity of compound of Formula |1 according to claims 1 or 10 is and - one or more solid-phase extraction cartridges/columns for the purification of compound of Formula I according to claim 1.
AU2010321278A 2009-11-17 2010-11-06 Method for production of F-18 labeled glutamic acid derivatives Ceased AU2010321278B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075508 2009-11-17
EP09075508.3 2009-11-17
PCT/EP2010/006766 WO2011060887A2 (en) 2009-11-17 2010-11-06 Method for production of f-18 labeled glutamic acid derivatives

Publications (2)

Publication Number Publication Date
AU2010321278A1 true AU2010321278A1 (en) 2012-05-31
AU2010321278B2 AU2010321278B2 (en) 2014-08-14

Family

ID=43933363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010321278A Ceased AU2010321278B2 (en) 2009-11-17 2010-11-06 Method for production of F-18 labeled glutamic acid derivatives

Country Status (15)

Country Link
US (1) US20130149243A1 (en)
EP (1) EP2501663A2 (en)
JP (1) JP2013510891A (en)
KR (1) KR20120101452A (en)
CN (1) CN102712552B (en)
AR (1) AR080670A1 (en)
AU (1) AU2010321278B2 (en)
BR (1) BR112012011786A2 (en)
CA (1) CA2780930A1 (en)
HK (1) HK1177928A1 (en)
IL (1) IL219698A0 (en)
MX (1) MX2012005733A (en)
RU (1) RU2012124810A (en)
TW (1) TW201121572A (en)
WO (1) WO2011060887A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107753962A (en) 2010-12-09 2018-03-06 通用电气健康护理有限公司 radioactive tracer composition
EP2520557A1 (en) * 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Novel precursors of glutamate derivatives
US9546193B2 (en) 2013-10-24 2017-01-17 The Regents Of The University Of California Compositions and methods for 18F-fluorodeoxyglycosylamines
CN113019279A (en) * 2021-03-11 2021-06-25 山西医科大学第一医院 Automatic synthesis device for preparing radiopharmaceuticals and using method thereof
WO2023229997A1 (en) * 2022-05-23 2023-11-30 Board Of Regents, The University Of Texas System Cgmp-compliant automated [18f]fspg production for clinical examination

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774243B2 (en) * 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
CA2421507A1 (en) * 2000-09-01 2002-03-07 Karina Aprico Screen for glutamate reuptake inhibitors, stimulators, and modulators
EP1539250A1 (en) * 2002-08-02 2005-06-15 Mallinckrodt Inc. Radioactively labelled amino acid analogues, their preparation and use
GB0422004D0 (en) * 2004-10-05 2004-11-03 Amersham Plc Method of deprotection
EP2123621A1 (en) * 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (1), application thereof and method for their manufacture
EP2086924B1 (en) * 2006-11-01 2018-09-12 Piramal Imaging SA [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation
EP1923382A1 (en) * 2006-11-18 2008-05-21 Bayer Schering Pharma Aktiengesellschaft [18F] labelled L-glutamic acid, [18F] labelled glutamine, their derivatives, their use and processes for their preparation
EP2123619A1 (en) * 2008-05-20 2009-11-25 Bayer Schering Pharma AG New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (II), application thereof and method for their manufacture
EP2123620A1 (en) * 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
JP2011526267A (en) * 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト Compound and radiopharmaceutical production method

Also Published As

Publication number Publication date
AU2010321278B2 (en) 2014-08-14
HK1177928A1 (en) 2013-08-30
WO2011060887A3 (en) 2012-04-12
CA2780930A1 (en) 2011-05-26
EP2501663A2 (en) 2012-09-26
AR080670A1 (en) 2012-05-02
KR20120101452A (en) 2012-09-13
IL219698A0 (en) 2012-07-31
TW201121572A (en) 2011-07-01
RU2012124810A (en) 2013-12-27
JP2013510891A (en) 2013-03-28
CN102712552A (en) 2012-10-03
BR112012011786A2 (en) 2019-09-24
MX2012005733A (en) 2013-01-22
CN102712552B (en) 2015-07-22
US20130149243A1 (en) 2013-06-13
WO2011060887A8 (en) 2011-10-20
WO2011060887A2 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
AU2010321278B2 (en) Method for production of F-18 labeled glutamic acid derivatives
EP2520556A1 (en) Radiolabeled amino acids for diagnostic imaging
KR20100075547A (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
JP5829613B2 (en) Homoglutamic acid derivative
JP2016028103A (en) Method for production of f-18 labeled amyloid beta ligands
WO2010063403A2 (en) Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
Wüst et al. Synthesis of 4-([18F] fluoromethyl)-2-chlorophenylisothiocyanate: A novel bifunctional 18F-labelling agent
WO2011151281A1 (en) Method for production of f-18 labeled amyloid beta ligands
US20120093726A1 (en) Radiolabeled Fluorine Derivatives of Methionine
EP2322171A2 (en) Fluorine labeled L-glutamic acid derivatives
WO2022189304A2 (en) Aliphatic 18f-radiolabeling of a tetrazine precursor
JP2013532136A (en) Method for producing F-18 labeled amyloid beta ligand
MX2014004274A (en) Improved method for production of f-18 labeled a㟠ligands.

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PIRAMAL IMAGING SA

Free format text: FORMER APPLICANT(S): BAYER PHARMA AKTIENGESELLSCHAFT

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BERNDT, MATHIAS; SCHMITTWILLICH, HERIBERT; FRIEBE, MATTHIAS; GRAHAM, KEITH; BRUMBY, THOMAS; HULTSCH, CHRISTINA; WESTER, HANS-JURGEN AND WAGNER, FRANZISKA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired